Archive for April, 2022

- Collaboration combines Quell's pioneering autologous multi-modular Treg cell therapy platform and Cellistic's expertise in iPSC cell therapy platform development and scale-up

- Aims to accelerate the development of a next-generation allogeneic Treg platform that could open significant opportunities for Quell's creation of off-the-shelf Treg cell therapies targeting a wide range of diseases driven by immune dysregulation

- First announced collaboration for Cellistic, Ncardia's recently formed cell therapy process development and manufacturing services business

LONDON and GOSSELIES, Belgium, April 27, 2022 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, and Cellistic,the iPSC-focused cell therapy process development & manufacturing partner recently launched by Ncardia to make large-scale allogeneic cell therapy production a reality,announce they have entered into a strategic collaboration for the co-development of an iPSC-derived Treg cell therapy platform. The goal of the partnership is to facilitate the future expansion of Quell's autologous Treg cell therapy pipeline by adding off-the-shelf, allogeneic Treg cell therapy products, leveraging Cellistic's expertise in differentiation and scale-up of iPSC processes for allogeneic cell therapy applications.

Iain McGill, Chief Executive Officer, Quell Therapeutics,said: "Quell has made significant progress advancing the first candidate from our autologous multi-modular Treg cell therapy platform into the clinic, with the initiation of our LIBERATE study of QEL-001 to prevent liver transplant rejection. We believe there is significant opportunity to transform outcomes for patients with QEL-001 and other autologous Treg cell therapy products in our pipeline. Our collaboration with Cellistic is a key building block in our investment towards a future, next-generation allogeneic Treg cell platform, which could significantly expand our opportunities to develop novel off-the-shelf treatments across a wide range of diseases driven by immune dysregulation. We highly respect the expertise and experience of Ncardia and the Cellistic team, and its track record in developing rapidly scalable iPSC cell therapy processes."

Stefan Braam, Chief Executive Officer, Cellistic,said: "Our partnership with Quell is emblematic of why we started Cellistic to bring together our focus and expertise in the development and implementation of iPSC cell therapy platforms with companies like Quell that have an equal depth of expertise in therapeutic development and share our vision for the future of cell therapy. We are excited to collaborate with the Quell team, both to develop the platforms, and to support Quell's long-term supply needs as they deliver impactful therapeutics to patients."

Under the terms of the agreement, Quell and Cellistic will collaborate in joint research to develop a process for differentiating iPSCs into highly functional Treg cell therapy products. Quell will contribute its Treg expertise and engineering technologies, as well as characterizing resulting Treg cells, while Cellistic will be responsible for the iPSC process science and development activities.

Based on a successful research phase, the collaboration will enter a product development phase with Quell having exclusive rights under the co-developed iPSC-Treg process for the development of multiple allogeneic iPSC-Treg cell therapeutics, and Cellistic as the exclusive CDMO partner for Quell's iPSC-Treg product pipeline, leveraging Cellistic's ongoing investment in downstream GMP capabilities.

Tracey Lodie, Chief Scientific Officer, Quell Therapeutics,added: "We have learnt in cell therapy development that the continuity from the R&D phase into the manufacturing phase is a critical success factor in achieving robust, scalable cell product processes. Cellistic emerged as a best-in-class and complementary partner to enable our path to an iPSC Treg cell therapy platform, and its ongoing investment in GMP capabilities provides the potential for a long-term partnership to accelerate the future development of allogeneic Treg cell therapies for patients."

About Quell Therapeutics

Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.

The Company is leveraging its pioneering phenotype lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency and stability than earlier generations of Treg cell therapy approaches.

Quell's lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases. http://www.quell-tx.com.

About Cellistic

Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. Its focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development positions the business to be the partner of choice for innovative cell therapy developers to commercialize novel advanced therapies. Leveraging more than a decade of Ncardia's scientific and technical knowledge and experience, Cellistic possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC-based cells that deliver quality products at scale. For more information, visit http://www.cellistic.com.

About Ncardia

Ncardia is a leader in contract research, development and manufacture of iPSC-based solutions for early and preclinical drug discovery. Its goal is to enable pharmaceutical and therapeutics companies to make more confident decisions in discovery and development by integrating iPSC technologies into their screening processes. Ncardia's capabilities include disease modeling, manufacturing, assay development and high-throughput screening especially for cardiac and neurodegenerative diseases. Ncardia was founded in 2011 and is majority-owned by KINICITI a private equity-backed advanced therapies platform. For more information, visit http://www.ncardia.com

Contacts for Quell TherapeuticsLuke Henry, Chief Business OfficerQuell Therapeutics[emailprotected]

Media: Mark Swallow, Sandi Greenwood, Eleanor PerkinMEDiSTRAVA Consulting+44 203 928 6900[emailprotected]

Investors: Christina TartagliaStern Investor Relations, Inc.+1 212 362 1200[emailprotected]

Contacts for Ncardia/CellisticAndy Holt, Chief Commercial OfficerCellistic[emailprotected]

SOURCE Quell Therapeutics and Cellistic

View post:
Quell Therapeutics and Cellistic enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform - PR...

TORONTO--(BUSINESS WIRE)-- Highland Therapeutics Inc., a privately held pharmaceutical company that through its wholly owned subsidiary, Ironshore Pharmaceuticals Inc., is focused on the commercialization of JORNAY PM (methylphenidate HCl) extended-release capsules (CII) for patients with ADHD, today announced the appointment of Stephanie C. Read as President/Chief Executive Officer, the appointment of Scott Myers as Chair of the Board and the additions of Kevin Bain and Ildiko Mehes as independent members of the Board of Directors. Stefan Antonsson, who has been serving as interim CEO will return to his role as an independent director.

It is my pleasure to congratulate Ms. Read in her transition from the Board of Directors to President/CEO, said Scott Myers, recently appointed Chair of the Board. Ms. Reads leadership in product development, corporate strategy, business development and specialty care commercialization will be key to driving sustainable growth with JORNAY PM, while enabling diversification into new therapeutic areas. I look forward to working closely with her to create value for patients, our employees and stakeholders."

The Board is grateful to interim CEO Stefan Antonsson for providing strategic direction and leadership continuity as we completed the financial restructuring of the company. After a brief transition, Stefan will return to his role as an independent member of the Board of Directors.

Commenting on her appointment, Ms. Read said, Highland and its subsidiaries are a rare instance of a privately held company with an exciting commercial product and experiencing rapid growth. I am pleased to join this seasoned executive team who have been successful in developing and launching JORNAY PM. With new capital from our shareholders and fresh perspectives from the new Board, we have the opportunity to continue to develop our products, people, processes and culture as we explore additional populations who may benefit from JORNAY PM."

Board of Directors:

Scott Myers, Chair of Board

Mr. Myers is a proven executive who brings nearly three decades of global pharmaceutical and medical technology most recently as CEO of AMAG, sold to Covis Pharmaceuticals, SA in November of 2020. Mr. Myers is a serial CEO, serving as Chairman and Chief Executive Officer of Rainier Therapeutics, a clinical-stage biotechnology company focused on metastatic bladder cancer that was purchased by Fusion Pharmaceuticals in March of 2020. Prior to joining Rainier, Mr. Myers served as Chief Executive Officer, President and as a director of Cascadian Therapeutics Inc. prior to its acquisition by SeaGen in March of 2018. Mr. Myers also served as Chief Executive Officer of Aerocrine AB, a medical device company from 2011 to 2015 prior to its acquisition by Circassia. Mr. Myers is currently an independent director of Selecta Biosciences where he serves as the Chair of the Compensation and Benefits Committee, as well as a member of the Nominating and Governance Committee. Mr. Myers also serves as the Chairman of the Board and Chairman of the Nomination and Governance committees and is a member of the Audit Committee for Harpoon Therapeutics, a clinical stage oncology company. Mr. Myers is also Chairman of the Board for Sensorion, SA, a gene therapy company focused on inner ear diseases. Mr. Myers is also Chairman of the Board of Dynavax Technologies, a Hepatitis B vaccine and COVID Adjuvant commercial stage company.

Stefan Antonsson, Independent Director

Mr. Antonsson has over 30 years of commercial experience in the pharmaceutical industry, primarily as a senior marketing executive, and he has established a proven track record of contributing to the success of rapidly growing pharmaceutical companies. Stefan was a key member of the Richwood/Shire senior management team and played a leadership role in launching Adderall and developing Adderall XR, acquiring and launching Carbatrol, and initiating the development of Intuniv. Stefan has also held senior marketing positions with Pharmacia and Forest Laboratories and executive positions with Vela Pharmaceuticals and Xanodyne Pharmaceuticals. Stefan has also been involved in several entrepreneurial ventures which successfully developed, licensed, and commercialized CNS products. Stefan also completed a long-term consulting assignment as Senior Vice-President of Marketing for Supernus Pharmaceuticals where he was part of the senior management team that established the commercial function for the company and successfully launched two anti-epilepsy drugs. Stefan earned his BA from Columbia College and MBA from The Stern School of Business, NYU.

Kevin Bain, Independent Director and Chair of Audit Committee

Mr. Bain is currently Chief Corporate Development Officer of Cell Research Corporation, a Singapore-based biologics company. This is a clinical-stage company developing a platform of products using stem cells from the umbilical cord lining membrane. From early 2006 through mid-2020, Kevin worked in the generic pharmaceutical and biosimilar business in companies founded and led by Robert Wessman. Kevin joined Alvogen in August 2009 as Chief Financial Officer, with responsibility for all Finance and Information Technology functions for the global Alvogen business. In November 2015, Kevin moved to a sister company named Alvotech as Chief Financial Officer. He has led several financing rounds, raising more than $1.5 billion in total value. Prior to joining Alvogen and Alvotech he spent almost four years with Actavis as Vice President of Finance for the US business of Actavis. From mid-2001 to early 2006, Mr. Bain was VP of Finance with a division of Danaher Corporation. From 1979 to 2001, Mr. Bain held positions of increasing responsibility within the finance organization of the Johnson & Johnson Family of Companies in both Canada and the US, including Vice President of Finance for J&J Medical Products. Mr. Bain graduated from the Accounting program at Fanshawe College in London, Ontario, Canada, and later earned his Certified Management Accountant (CMA) designation. Kevin is currently a Board member and Chair of the Audit Committee of Akorn Pharmaceuticals, a leading US-based specialty pharmaceuticals company.

Ildiko Mehes, Independent Director

Ms. Mehes is an advisor to investment management firms, consulting firms and pharmaceutical companies about a wide range of risks and opportunities in the pharmaceutical industry. She previously spent 12 years at Teva Pharmaceuticals in a variety of business and legal roles including, most recently, Senior Vice President & General Counsel. Her areas of responsibility in the U.S. and Canada spanned New Product & Portfolio, R&D, Regulatory Affairs, and Legal Affairs. She has extensive expertise in intellectual property, including related to ADHD drugs, and also has significant pharmaceutical M&A experience. Prior to Teva, Ildiko was a pharmaceutical patent and commercial litigator. Ildiko is admitted to the Bars of Massachusetts and Ontario, Canada. She is also the recipient of several awards, including the National Post/ ZSA Canadian General Counsel Award for Litigation Management and the Association of Corporate Counsels Global Award for Litigation Management. Ildiko holds a B.A. (Honors) in Economics from Queens University, a J.D. from Osgoode Hall Law School, both in Canada, and completed the Advanced Management Program at the Wharton Business School.

Stephanie C. Read, Chief Executive Officer

In addition to serving as the newly appointed President/CEO, Stephanie will continue to have a seat on the Board of Directors. Ms. Read also serves as a Non-Executive Director on the Board of ALSP Orchid Acquisition Corporation I. Ms. Read's 24-year biopharmaceutical career spans Global Research and Development, Medical Affairs, Alliance Management, Commercial and Business Development and Equity Investing. All leadership roles have included driving transformational change within organizations to accelerate top- and bottom-line growth, and diversification of company portfolios. Ms. Read's therapy area expertise includes Psychiatry (inventorship of MYDAYIS), Gastroenterology, Oncology & Pain, Infectious Disease, Immunology and Rare Diseases. Ms. Read's industry appointments include the last 6.5 years with CSL as global VP, Corporate Strategy and Business Development, 7.5 years with AstraZeneca/MedImmune in a variety of Medical Affairs, Commercial and Business Development roles, and over six years with Shire PLC in R&D and Global Medical Affairs (including inventing, developing and launching new treatments for ADHD). Stephanie holds a M.Sc. in Biotechnology from The Johns Hopkins University and a B.Sc. in Biology from Virginia Tech.

WARNING: ABUSE AND DEPENDENCE

See full prescribing information for complete boxed warning.

See additional important safety information below.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including JORNAY PM, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

PREGNANCY AND LACTATION

Please visit http://ironshorepharma.com/labeling.pdf for additional important safety information and the Full Prescribing Information, including Boxed Warning, for JORNAY PM.

About Highland Therapeutics Inc.

Highland Therapeutics Inc. is a pharmaceutical company whose mission is to develop and commercialize innovative, patient-centric treatment options. Based in North Carolina, subsidiary Ironshore Pharmaceuticals Inc. is responsible for the sales, marketing and distribution of pharmaceutical products within the US. Based in Grand Cayman, subsidiary Ironshore Pharmaceuticals & Development, Inc. develops novel therapeutics by leveraging its proprietary drug-delivery technology.

Forward-Looking Statements

This press release contains forward-looking information, which reflects the companys current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the companys control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, the company assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006027/en/

View original post here:
Highland Therapeutics Announces Appointment of Stephanie C. Read as President/CEO, Changes to Board of Directors - BioSpace

Inflammation represents one of the leading drivers of disease. Biotech company 180 Life Sciences is developing novel, anti-TNF therapies for treating distinct inflammatory diseases.

DocWire News spoke to James Woody, CEO of 180 Life Sciences, to learn more about the company, its mission, its treatment assets, and current clinical trials its involved in.

*Interview recorded in March 2022.

DocWire News: Can you give us some background on yourself, and the company, 180 Life Sciences?

James Woody: So by background, Im a pediatric immunologist, and in my prior life, I was Chief Scientific Officer of a company called Centocor, which was one of the very early biotech companies. And we were the first ones ever to make a anti-TNF antibody and to test it in patients, and we were able to show that it was remarkably effective in patients with rheumatoid arthritis, Crohns disease and psoriasis and ulcerative colitis. And that actually began the pretty much the whole antibody based biologics industry. We were the first ones to do this with a humanized antibody.

I went on from there to run a pharmaceutical company called Syntex, former Syntex that was after Roche bought it and did that for eight years, we invented a lot of small molecules. And then I went on to start a company in oncology, cancer stem cells. And from there I went over to the dark side and joined a venture capital group and helped start companies for about 10 years and some of them are really successful. Some of them are okay and some crashed and burned, but thats the nature of the business. And then more recently I helped start a couple companies on my own. And then I was approached by the founders of 180 LS to help them out and also to be CEO of their company, so thats how I came to be CEO of 180 Life Sciences.

180 Life Sciences is repurposing anti-TNF for unmet needs. What is anti-TNF?

So in your body, you have lots of protein circulating around in your blood. These tell the body cells what to do, and some of them are called cytokines and cytokines are the ones that kind of tell your immune system what to do. And theres quite a lot of these. And theres some of em that are very good. Theres some of them that are bad actors and one of them is called tumor necrosis factor. It was named that totally by accident because it seemed to eliminate tumors in mice, but thats never been able to be shown in humans, but the name has stuck with it. So tumor necrosis factor is the thing that causes some types of inflammation, if theres an overproduction. For example, in rheumatoid arthritis, its the tumor necrosis factor that drives the destruction of the joints of your fingers and knees and shoulders and everything, so its a destructive cytokine. And what we did is we made a specialized antibody against TNF that binds it up and blocks it and prevents it from causing the inflammation. And that was the basis of infliximab or Remicade that we discovered from Centocor.

What is Dupiytrens disease, how is it characterized?

Dupuytrens Contracture is kind of a chronic disease, but it affects quite a lot of people, maybe 16 or 20 million in the US, same in Europe. It starts out as a small nodule in your palm. And over time, maybe a couple of years, some faster, some slower, it begins to form cords underneath the palm of your hand, it pulls your fingers together and contracts them. Sometimes this is inherited in families and sometimes it just occurs. So what happens is that this nodule starts, and as I said, over time, the fingers become contracted. So theres no therapies for the early stage when the nodules just form, but thats the basis of what were doing, Ill talk about that in a minute.

Later on, after the fingers are already contracted and you have the disability, you cant button your clothes, you cant type with that hand. You cant do many of the things that you like to do with your hand. Theres several therapies that they try. One of them is injecting a collagenase thats partially effective, but they all, about half of those recur. You can try to disrupt these cords with a needle called needle aponeurectomy or alternatively, what happens is you end up going to surgery and they cut these cords out. Ironically, my wife had this and went through a whole year of steroid injections into her hand, finally had to have the surgery. So Im familiar with the process. But thats what happens, and I think people, as soon as the nodule forms, people these days, because they have Dr. Google, can immediately know whats going to happen in the long run, so the information out there is quite impressive.

180 Life Sciences recently completed a Phase 2 study for Duputyrens. Tell us about the study protocol, the drug used and other updates on the study.

Our colleague in England, Dr. Jagdeep Nanchahal, was able to look at Dupuytrens Contracture and especially the nodules, and through a series of very elegant experiments, he was able to show that the nodule was driven by the TNF, the bad actor. And in this case, the inflammation caused the fibrosis that were talking about, that leads to the finger contracture. And so he was able to work out that if you inject anti-TNF into this nodule, you can impact the course of the disease.

And so he did a very large trial of about 150 patients in the UK and was able to inject anti-TNF into the nodules of their hands. And in that trial, which took over a year, there were three or four injections, but we were able to show that both the primary and secondary endpoints of the trial were met and the endpoints had to do with the size of the nodule, whether it was growing, whether it was shrinking, whether it was hard or whether it was soft or whether the fingers were contracting, all of that, but we met the primary endpoints and the full publication with all the details will be out, hopefully in the next couple of months.

You have another trial planned for Frozen Shoulder. What is Frozen Shoulder, and how will the trial aim to address it?

Yes, Frozen Shoulder is another kind of inflammatory condition where fibrosis forms in the shoulder. And it initially starts out as being extremely painful. And that goes on for several months and then eventually the pain subsides, but the shoulder becomes totally immobile. And eventually you have to have surgery to remove the fibrotic tissues. Interestingly enough, this occurs more common in patients with diabetes, but about half of those patients also have Dupuytrens. And so we think that the fibrosis in the Dupuytrens and the fibrosis in the shoulder is the same mechanism. And so Dr. Nanchahal will be injecting anti-TNF into the shoulder very early, as soon as the pain is evident, then hell try to inject anti-TNF and maybe relieve the pain and also the formation of the fibrosis, so that one can avoid the surgery, which is actually quite expensive. And also, theres quite a long course of physical therapy after the surgery, so its something youd like to avoid. And so were trying to treat patients both with Dupuytrens and Frozen Shoulder before the disability develops.

A third program, which is soon to be clinical, is anti-TNF for post-operative cognition delirium or POCD. Tell me about POCD, and the preliminary research that led the team to pursue this indication?

We know that now that theyre doing fairly aggressive surgery in older patients, either hip replacements or emergency hip corrections or CABG procedure, coronary artery bypass graft, or cardiac surgery, that a fair percentage of these people after the surgery, just have a foggy brain. And the fog goes on for some time and we call it postoperative cognitive dementia, as the technical term. And in some patients, maybe 15 or 20%, it doesnt go away. And they end up in nursing homes and they actually dont live very long after that. And so our colleagues in the UK, Dr. Nanchahal and Dr. Feldman and his colleagues, have shown that during the surgery, any kind of aggressive surgery, that TNF is released from the tissue damage, and the TNF goes to the brain and opens it up and lets inflammatory cells get into the area of the brain thats where your cognitive areas are, and so that leads to the dementia.

And in the past, theyve thought this all had to do with the anesthesia, but we think its the TNF thats actually causing this dementia going forward. And so were actually going to do a trial in patients that are having their hip repaired that are older, and were going to administer one dose of anti-TNF just before the surgery starts with a view towards preventing the dementia going forward. So this will be a long trial, but if it works, itll be something that everybody who goes into major surgery would want to have. So its another exciting opportunity for 1-ADLS and our investigators.

180 Life Sciences recently announced licensing of a compound called HMGB1. Tell us more about HMGB1 and the companys plans for it.

The company is also working on other areas of fibrosis, not just Dupuytrens Contracture and Frozen Shoulder, but other areas like liver fibrosis, which occurs with NASH. And we are working on ways to prevent that as well, much like were working on Dupuytrens and Frozen Shoulder. The fibrosis in the liver is really hard to reverse, and there are no real agents that do that, but theres a lot of people trying different things. Now what the HMGB-1 does, it doesnt change the fibrosis, but once the fibrosis is stopped, it could help the liver cells to regenerate. So this is kind of a regenerative medicine. It makes the tissues regenerate, whether its heart or whether its liver or whether its lung or whatever. And so its going to be used after the fibrosis is stopped. And so thats kind of what were interested in. And were just getting that program off the ground and making the initial compounds to do our testing.

Any closing thoughts?

Well, Id like to talk about our team. The company was founded by Dr. Mark Feldman, who was the one, he was the original person who figured out that TNF was causing the joint destruction and arthritis, and with TNI and others, that actually did the very first trials ever. And this was done in patients with wheelchairs and they actually got up out of their wheelchairs and walked around. It was a phenomenal moment. We had no idea it would work that well. And some of them actually did a pirouette down some stairs. We have videos of this. So its kind of like The Awakening movie where they gave them the L-DOPA and they all woke up. Well, in this case, they got up out of their wheelchairs and theres no patients in wheelchairs with rheumatoid arthritis in the whole world because of that drug, and the ones that followed on.

The current Humira from AbbVie is the preferred one. But the whole idea and concept, we started back then. Other founders, Dr. Larry Steinman, he and Mark put the 1-ADLS together. And he developed Tysabri, the very first drug to help MS patients. And it was another phenomenal discovery that he made. And hes also working on MS and other areas. But so we have the leaders in inflammation as the people who actually founded the company. So its a pleasure to work with them. Ive been acquainted with them off and on for the past, maybe 25 years, so working with them again is a real pleasure.

Read more here:
James Woody, CEO of 180 Life Sciences: Developing New Therapies to Treat Inflammatory Diseases - DocWire News

Enter genomic DNA sequence to find CRISPR target sites:(Omit header lines and special characters.)

Select genome:

---- Drosophila melanogaster ---- Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila melanogaster (reference genome, r_6) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila melanogaster (vas-cas9 III, BDSC 51324) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila melanogaster (nos-cas9 II, BDSC 78781) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila melanogaster (nos-cas9 III, BDSC 78782) ---- Other Drosophila Species ---- Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila ananassae (dana_r1.3_FB2011_07) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila erecta (dere_r1.3_FB2011_08) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila eugracilis (GCA_000236325.2) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila grimshawi (dgri_r1.3_FB2010_02) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila mauritiana (Dmau_MS17) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila mojavensis (dmoj_r1.3_FB2011_05) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila persimilis (dper_r1.3_FB2010_02) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila pseudoobscura (dpse_r3.1_FB2013_03) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila sechellia (droSec1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila simulans (DsimV2) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila simulans (droSim1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila virilis (droVir3) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila willistoni (dwil_r1.3_FB2010_02) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Drosophila yakuba (droYak2) ---- Other Organisms ---- Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Acyrthosiphon pisum (2) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Aedes aegypti (AaegL5.0 GCA_002204515.1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Anopheles gambiae (strain M) (AgamM1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Anopheles gambiae (strain S) (AgamS1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Apis cerana cerana (GCA_002290385.1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Apis mellifera (apiMel3) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Bombus impatiens (GCA_000188095.2) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Caenorhabditis elegans (ce10) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Ceratitis capitata (1.1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Daphnia pulex (GCA_900092285.1_ASM90009228v1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Daphnia pulex (GCA_000187875.1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Lutzomyia longipalpis (GCA_000265325.1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Manduca sexta (GCA_000262585.1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Nasonia vitripennis (2.1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Oncopeltus fasciatus (GCA_000696205.2) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Paracoccus denitrificans (GCA_000203895.1) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Rhodnius prolixus (GCA_000181055.3) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Schistosoma mansoni (GCA_000237925.2) Notice: Undefined index: genomeSelect in /var/www/html/genome-select.inc on line 56 Tribolium castaneum (Tcas 4.0 draft)

Read the original:
CRISPR Optimal Target Finder

Albany NY, United States: CRISPR cas systems are commonly used in microbial engineering that includes immunization of cultures, bacterial strain typing, and self-targeted cell killing. Further, CRISPR and cas genes market system is also applied to control metabolic pathways for an improved biochemical synthesis. This technology is also used for the improvement of crop production. These factors further drive growth in the CRISPR and cas genes market.

CRISPR and cas genes system has been a revolutionary initiative in the biomedical research field. The application of this technology in somatic cell genome editing events has targeted to its application. The technologies are commonly used for the treatment of different genetic disorders. But, the ethical issues while using the system from the CRISPR and cas genes market are somewhere curtailing the growth in the industry. Furthermore, the market is also witnessing a lack of proficient professionals, which restrains its growth opportunities.

Request a PDF Sample https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26417

The market forecast on CRISPR and cas genes market was estimated US$ 1,451.6 Mn. Now it is predicted to climb US$ 7,234.5 Mn during forecast period from 2018 to 2026. The market is estimated to reach a compound annual growth rate (CAGR) of 20.1% from 2018 to 2026.

Multiple Applications and Diverse Dominating Factors in CRISPR and Cas Genes Market

The report from market research on CRISPR and cas genes industry has marked its division on the basis of region, end-user, application, and product type. DNA-free cas and vector-based cas are the two types in which the CRISPR and cas genes market is bifurcated on the basis of product type. Between these two types, the vector-based cas section has dominated the market at international levelin 2017. This expression system is helpful for the researchers who are focusing to enrich Cas9-expressing cells and concentrate on the establishment of a stable cell line. The vector-based cas is available with an analytical that is used to support the creation of durable cell lines. These lines are designed with minimal possible background expression.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26417

The major advantages of the DNA-free cas segment boost growth in the CRISPR and cas genes market. DNA-free cas components are used for the reduction of potential off-targets. They also find application to trace correlations with human illnesses.

Knockout/activation, functional genomics, disease models, and genome engineering are the classification types in the CRISPR and cas genes market on the basis of application in different verticals. Contract research organizations, government and academic research institutes, pharmaceutical and biotechnology companies are some of the key end-use industries in the market. Further, as per the market analysis report on CRISPR and cas genes market, the industry is spread in different regions that include Middle East & Africa, Latin America, Asia Pacific, Europe, and North America.

Request for Analysis of COVID-19 Impact on CRISPR and Cas Genes Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=26417

The industry players from market have adopted inorganic and organic growth strategies for the expansion of product offerings, capturing market share, increasing consumer base, and strengthening geographical reach. Some of the key players in the CRISPR and Cas genes market include Dharmacon, Synthego, GenScript, OriGene Technologies, Inc., Applied StemCell, Inc., Addgene, and Cellecta, Inc.

Genome Engineering to Dominate CRISPR and Cas genes market

On the basis of application, the genome engineering section has dominated in the CRISPR and cas genes market. The genetic materials can be added, detached, and altered with the help of CRISPR technology at any specific location in the genome. Genomic engineering is related to the synthetic assembly of comprehensive chromosomal DNA, and it has been commonly taken from natural genomic sequences.

Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=26417

The CRISPR and Cas genes market has been dominated by pharmaceutical and biotechnology companies in terms of end-user. The strategic partnerships and innovations may boost growth in the market.

North America and Europe are the regions that account for the maximum share in the CRISPR and Cas genes market. Rising technological advancements and research activities are driving growth in the market.

Browse more Reports by Transparency Market Research:

High-flow Nasal Cannula Market: The global high-flow nasal cannula market is expected to be driven by the technological progress made by the prominent market players. In addition to that, clinical trials for the purpose of evaluation of new areas of application are likely to open up new avenues of growth for the global high-flow nasal cannula market in the years to come.

Blood Group Typing Market: The global blood group typing market is prophesied to gain impetus from the increasing number of applications in various types of tests. As noted by experienced analysts, antibody screening could draw a greater growth in the market due to the intensifying demand for the early diagnosis of diseases and swelling prevalence of chronic diseases.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

More here:
CRISPR and Cas Genes Market is Anticipated to Reach US$ 7,234.5 Mn by 2026, Increase in Incidence of Genetic Disorders to Drive the Market - BioSpace

Ive combed the internet to find you todays most fun/important/scary/fascinating stories about technology.

1 Elon Musk is buying Twitter for $44 billionHes unlikely to enjoy owning it as much as he thinks he will.(The Atlantic $)+ Heres a recap of the past fortnight: a rollercoaster ride from beginning to end. (FT $)+ Musk claims that open sourcing Twitters algorithm will make it more transparent. (NYT $)+ Trump says he wouldnt rejoin, but his advisers arent convinced. (WP $)+ Musk thinks people might be willing to pay for Twitter. Good luck with that. (Protocol)+ Its prompting people to finally face up to their Twitter addictions. (Input)

2 How China wrote the playbook for censoring covid informationIts inspired many other countries to impose restrictions in the name of public health. (New Yorker $)+ A new covid outbreak in Beijing is heightening fears of a Shanghai-style lockdown. (NYT $)+ Fences have been erected in Shanghai to prevent residents from leaving their homes. (BBC)

3 Instagram hackers stole $3 million of Bored Ape Yacht Club NFTsThey managed to compromise the official Instagram account then use it to post a phishing link. (Bloomberg $)+ Of course theres a social network for NFTs in the works. (Quartz)+ Chinese NFT platforms dont want you to trade NFTs anymore. (TR)

4 Conspiracy theories are nothing to do with evidenceAnd everything to do with how they make us feel. (Wired $)+ We are living in an age of misinformation. (Vox)

5 The US is fighting back against Chinas chip dominanceBy keeping its most advanced chipmaking tools to itself. (The Economist $)+ The great chip crisis threatens the promise of Moores Law. (TR)

6 The crypto industry is on a lawyer hiring spreeTo go mainstream, you need legal smarts. (WSJ $)+ Dogecoin, Elon Musks favorite cryptocurrency, is surging after his Twitter purchase. (Bloomberg $)+ A deep dive into the mysterious subcultures of cryptocurrency obsessives. (SCMP)+ Its okay to opt out of the crypto revolution. (TR)

7 The metaverse is a vile quagmire of racism, rape jokes and assaultAnd theres next to no recourse for offenders, either. (The Guardian)+ It doesnt help that were struggling to define what the metaverse even is. (Wired $)+ Facebook is opening its first physical store to try to sell its metaverse-related gadgets. (WP $)

8 Europes wind energy companies are being targeted by cyberattacksRenewable energy is an increasingly attractive target for criminals as attention turns to oil and gas alternatives. (WSJ $)

9 Coders want to relieve low-income families of the burden of adminApplying for benefits is needlessly complicated. (The Atlantic $)

10 Adapting video games for TV is so difficult to get rightBut makes for great watching when it works. (The Guardian)+ Nintendos animated Super Mario Bros. movie has been delayed. (The Verge)

Link:
The Download: Fertility for trans men, and a Q&A with CRISPR's co-creator - MIT Technology Review

BERKELEY, CAAdmitting he felt self-conscious following a workplace accident involving the highly experimental gene-editing technology, a local half-lobster scientist told reporters Friday he would just have to hope his coworkers didnt notice his CRISPR mishap. The main thing I need to do is make sure I dont slip up and try to shake someones hand, because that would be a dead giveaway, said University of California, Berkeley, microbiologist Steven Lipstadt, using his gigantic claws to put on a novelty sombrero he had purchased on his lunch break in order to hide the long antennae projecting outward from his head. Luckily my lab coat covers up quite a bit of my tail, so as long as I stay behind my desk, no one should notice that. Maybe people will see my protruding crimson rostrum and think I just have a cold or something? Ugh. If anyone notices I look a little different today, Ill tell them I got a haircut. I just hope nobody here has a shellfish allergy. At press time, Lipstadt was reportedly worried the nighttime cleaning staff would discover the half-human lobster he had been forced to smother with a couch cushion and stuff into a trash can.

Link:
Half-Lobster Scientist Just Going To Hope Coworkers Dont Notice He Had Mishap With CRISPR - The Onion

(Ryan Downie)

Stocks with huge growth potential usually come with additional risk. Stock valuations usually reflect potential gains, but companies with fantastic upside potential usually face tons of uncertainty. That's not necessarily a bad thing, but we all need to make informed decisions when building our portfolios. Every investor needs to figure out their ideal balance of risk and reward and allocate accordingly.

These two stocks might be too risky for some investors, but people who take the plunge could reap major rewards down the road.

Image source: Getty Images.

1. Zscaler

Zscaler (NASDAQ: ZS) is a cybersecurity stock that provides cloud-based software for large businesses. It focuses on edge security, ensuring that user devices are able to connect with an employer's network without compromising the data on that network. This is extremely important for any company with a distributed workforce. As working from home and remote collaboration become more common, these security services have become absolutely essential for any enterprise that aims to stay relevant in today's economy.

People are also reading

This makes Zscaler an exciting opportunity because it's occupying the right place at the right time. The story gets even more compelling when you consider Zscaler's leadership position and highly respected product portfolio. The company receives outstanding marks from Gartner, and it's commonly viewed as one of the leaders of its cybersecurity niche. This translates to high customer satisfaction, and its high net dollar retention rate above 125% is clear evidence that businesses are seeing lots of value in Zscaler products.

This has all translated to great financial results for Zscaler. The company reported 63% revenue growth last quarter. Its full-year forecasts call for an expansion of roughly 55% in sales. By the end of the year, Zscaler's annualized recurring revenue should be above $1.4 billion. The company isn't profitable on an earnings basis yet, but it produces positive free cash flow. That means that it can support its high growth without exhausting its financial resources, which is great for investors.

It's easy to see where Zscaler stock gets its upside. The risk comes entirely from valuation. The stock's price-to-sales ratio is over 33, and its PEG ratio is above 4. This is a fairly high level, even among promising growth stocks -- and its valuation ratios used to be nearly twice as high.

Zscaler's stock has experienced some wild valuation swings since its IPO in 2019, so investors should expect continued volatility. The current valuations already assume a ton of growth and strong cash flows, so the company needs to deliver phenomenal financial results just to meet expectations. That requires investors to take a leap of faith. If there's any indication that it could fall short of its aggressive goals, the stock is nearly certain to suffer big losses, at least in the short term. Even if the company continues to perform well, Zscaler stock can still take a beating if the market is moving downward due to macroeconomic issues.

2. CRISPR Therapeutics

CRISPR Therapeutics (NASDAQ: CRSP) is a gene editing technology company that could drastically disrupt the pharmaceutical and biotech markets. It's developing a number of medications for various serious illnesses, including various forms of cancer, sickle-cell disease, diabetes, and degenerative diseases. This could greatly improve patient outcomes while making treatment more efficient and affordable.

Gene editing is an emerging industry with no clear leader in the market. CRISPR has a number of medication candidates, and it's also engaged in joint ventures with high-profile partners such as Vertex Pharmaceuticals. There's a chance for CRISPR to secure early-mover status in a disruptive industry that's expected to grow nearly 20% annually over the next decade.

CRISPR's market cap is currently around $4.5 billion. If its treatments wind up being safe, effective, and affordable, its product portfolio should be worth much more than $4.5 billion, and investors could enjoy huge returns.

Like many biotech stocks, this great opportunity comes with plenty of risk. CRISPR doesn't have any revenue from commercial sales of its products. There are major regulatory hurdles to clear before it sells a single treatment. It also has to solve manufacturing, logistical, and marketing challenges once it receives approval for medications. CRISPR also faces competition from other gene-editing companies, as well as traditional drugmakers. There's a good chance that the company will need to raise more cash by selling shares or issuing debt before it becomes stable, which could impact its financial stability.

CRISPR is an exciting healthcare stock for sure, but it is also a high-profile boom-or-bust investment. It could play a role as a growth stock for many investors, but make sure that your portfolio is capable of handling the risk before you dive in.

10 stocks we like better than Zscaler

When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Zscaler wasn't one of them! That's right -- they think these 10 stocks are even better buys.

*Stock Advisor returns as of April 7, 2022

Ryan Downie has no position in any of the stocks mentioned. The Motley Fool owns and recommends CRISPR Therapeutics, Vertex Pharmaceuticals, and Zscaler. The Motley Fool recommends Gartner. The Motley Fool has a disclosure policy.

Get the latest local business news delivered FREE to your inbox weekly.

Read more:
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge - Lincoln Journal Star

This article was originally published here

Exp Biol Med (Maywood). 2022 Apr 27:15353702221090181. doi: 10.1177/15353702221090181. Online ahead of print.

ABSTRACT

COVID-19 is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus affecting the world population. Early detection has become one of the most successful strategies to alleviate the epidemic and pandemic of this contagious coronavirus. Surveillance testing programs have been initiated in many countries worldwide to prevent the outbreak of COVID-19. In this study, we demonstrated that our previously established clustered regularly interspaced short palindromic repeats (CRISPR)-Cas12a-based assay could detect variants of concern during 2021 in Thailand, including Alpha, Beta, and Delta strains as well as Omicron strain in early 2022. In combination with the newly designed saliva collection funnel, we established a safe, simple, economical, and efficient self-collection protocol for the COVID-19 screening process. We successfully utilized the assay in an active case finding with a total number of 578 asymptomatic participants to detect the SARS-CoV-2 in saliva samples. We finally demonstrated that the validation and evaluation in a large-scale setting could provide valuable information and elaborate the practicality of the test in real-world settings. Our optimized protocol yielded effective results with high sensitivity, specificity, and diagnostic accuracy (96.86%). In addition, this study demonstrates COVID-19 active case findings in low-resource settings, which would be feasible and attractive for surveillance and outbreak prevention in the future.

PMID:35473361 | DOI:10.1177/15353702221090181

Here is the original post:
COVID-19 active case findings based on self-collected saliva samples with CRISPR-Cas12a detection - DocWire News

The International Society for Pharmaceutical Engineering (ISPE) today announced the 2022 Facility of the Year Awards (FOYA) Category Winners at the 2022 ISPE Europe Annual Conference in Madrid, Spain.

NORTH BETHESDA, Md., April 26, 2022 /PRNewswire-PRWeb/ -- The International Society for Pharmaceutical Engineering (ISPE) today announced the 2022 Facility of the Year Awards (FOYA) Category Winners at the 2022 ISPE Europe Annual Conference in Madrid, Spain.

Awardees Include:

The FOYA judges' panel has also awarded Honorable Mention to:

FOYA is the premier global awards program recognizing innovation and creativity in manufacturing facilities serving the pharmaceutical industry. The award-winning projects selected by the FOYA program set the standard for pharmaceutical facilities of the future by demonstrating excellence in facility design, construction, and operations.

"The future of the pharmaceutical industry is being shaped every day by innovative companies worldwide. Companies like the 2022 FOYA Category Winners have a clear commitment to excellence and set the high bar for quality in the design and social impact consideration of their facilities," said Thomas Hartman, President & CEO, ISPE. "They incorporate a thoughtful, unique, and adaptive approach to innovation, operability, sustainability, and reliability while introducing flexibility allowing for the manufacturing of multiple product modalities. Further, these modern facility designs introduce digitization strategies that accelerate timelines from product development to product licensure. ISPE is proud to recognize these companies."

Story continues

ISPE 2022 Facility of the Year (FOYA) Category Awards Winners

The Innovation Category was awarded to CRISPR Therapeutics for its facility in Framingham, Massachusetts, USA. CRISPR Therapeutics has harnessed the CRISPR/ Cas9 gene-editing platform to develop and deliver potentially curative therapies to patients with serious diseases. The technology has game-changing implications for patients and partners. The project was awarded a FOYA award for Innovation based on the innovative design of the facility, which provides an end-to-end solution for production and fills operations. The FOYA judging committee commends CRISPR for creating a flexible, digitally enabled facility that can bring the promise of innovation to life.

Janssen Biologics, BV won the Project Execution Category for its Vaccine Launch Facility (VLF) Expansion in Leiden, The Netherlands. This Johnson & Johnson (J&J) biopharmaceutical production and laboratory testing facility produces clinical and commercial bulk active pharmaceutical ingredients and provides analytical testing services for J&J's global portfolio of vaccines. The existing VLF represented an opportunity to enable large-scale COVID-19 vaccine drug substance manufacturing by building a new, 25,000 square-foot sterile manufacturing facility adjacent to the existing VLF. This fast-tracked project was developed to design and build the new facility within nine months and to secure regulatory approval for initial commercial batches produced in the facility within 12 months. The ambitious timeframe required a Herculean effort and flawless collaboration on the part of all involved parties, including best-in-class design and construction partners and an integrated, cross-functional team within J&J.

Takeda Pharmaceuticals International AG won the Supply Chain Category for its Alofisel Global Program in Madrid, Spain; Grange Castle, Ireland; Osaka, Japan; and California, USA. Alofisel is a first-in-class stem cell therapy product and the first allogeneic mesenchymal stem cell therapy to receive approval by the European Medicines Agency. The project was designed with a product shelf life of only 48 hours and requires seamless cold chain transportation. Takeda had to completely rethink the supply chain to get the product from the plant to the hospital to be administered to the patient within a very short time frame. The program is recognized in this year's awards for its novel and innovative approach to end-to-end supply chain management as well as the program's innovative design in expanding the Alofisel manufacturing network from its initial plant in Madrid, Spain, to other regions across the globe with new facilities in the US, Japan, and Ireland.

The Pharma 4.0 Category was awarded to Takeda Pharmaceuticals International AG in Singen, Germany for its TaSiVa project. The TaSiVa facility took an innovative approach to the project of implementing pharma 4.0 technologies as part of the overall project delivery, which also complemented the companywide digital transformation. It included several key collaborations with suppliers and academia to develop pharma 4.0 solutions. The facility was built with state-of-the-art process equipment and then layered with advanced digital technologies in several key areas. A complete IT infrastructure upgrade was completed at the site during the early phase of the project thus providing the platform to utilize advanced information technology (IT)/ operational technology (OT) solutions as part of the project delivery. The project exemplifies how the application of innovation in advanced digital technologies leads to improved outcomes in terms of safety, product quality, and productivity in a pharmaceutical manufacturing facility.

The first of two companies to be awarded in the Social Impact Category is Catalent for its Project Mercury in Bloomington, Indiana. Catalent's Project Mercury was delivered in the face of the global pandemic. With an unknown manufacturing process for a vaccine candidate under development, the team pivoted on existing projects to ensure success, adding 40% more scope including secondary packaging and inspection. The project added 40,000 sq ft to cover the most stringent of the unknown needs of the process, reducing the risk to supply. The project team also cut six months off their schedule and beat the clock while managing the complexities of execution within the COVID-19 restricted environment and delivering the needed capacity to meet important pandemic demands. They applied a great amount of effort and budget into adding additional safety measures to keep workers safe throughout the constant threat of the COVID-19 virus along with including three major elements of sustainability into their plans for Project Mercury: People, Planet, and Profits.

The second of two companies to be awarded in the Social Impact Category is Janssen Biologics, BV for its Vaccine Launch Facility (VLF) Expansion in Leiden, The Netherlands. During the VLF expansion construction activities were executed during an increased level of positive COVID cases in The Netherlands. J&J kept the personal safety of all project team members as its top priority by implementing various safety measures to reduce the risk of exposure to the COVID virus. These additional safety measures resulted in no significant stoppages or slowdowns of work during construction.

Iovance Biotherapeutics, Inc. was awarded an Honorable Mention for its Iovance Cell Therapy Center (iCTC) in Philadelphia, Pennsylvania. With only one chance of success and Iovance having a production timeline of 22 days, there is no room for error when developing therapies. Their facility was designed with significant redundancies to support its operation 24 hours a day, 365 days of the year. Iovance had a goal to "be the first company in the world to commercially produce a personalized therapy for solid tumors" and as a relatively small company, their achievement in that first, as well as having an excellent facility was recognized by the judges.

The 2022 FOYA Category Winners will be formally recognized at the ISPE Facility of the Year Awards Banquet, held in conjunction with the 2022 ISPE Annual Meeting & Expo, taking place 30 October2 November 2022. The banquet will feature acceptance speeches from the FOYA recipients and presentations from noted industry leaders. The 2022 FOYA Overall Winner will be announced at the conference during the ISPE Membership Meeting and Awards Lunch on 1 November 2022.

About the ISPE Facility of the Year Awards Program Established in 2005, The Facility of the Year Awards (FOYA) recognizes state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and manufacturing industry to showcase its accomplishments in facility design, construction, and operation while sharing the development of new applications of technology and cutting-edge approaches. Visit ISPE.org/FOYA for more information.

About ISPE The International Society for Pharmaceutical Engineering (ISPE) is the world's largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancements across the entire pharmaceutical lifecycle. The 20,000 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit ISPE.org for more information.

Media Contact

Amy Henry, ISPE, 813-960-2105, ahenry@ispe.org

SOURCE ISPE

View post:
2022 ISPE Facility of the Year Category Award Winners Announced - Yahoo Finance

The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) segment is a leading segment in terms of revenue by product type in the gene editing tools market, and accounted for an approximate revenue share of 75% in 2018. CRISPR/Cas9 gene editing tools are most widely used by scientists to create transgenic animals that include zebrafish, pigs, mice, rats, and primates. Among all the distribution channels in the gene editing tools market, the academic and research institutes segment is expected to be most prominent segment, followed by biotech and pharmaceutical companies.

Prevalence of Cancers and Rare Genetic Diseases Establish a Strong Base for Innovation of Gene Editing Tools

The rising prevalence of cancer and other genetic disorders, such as sickle cell disease, heart disease, diabetes, Alzheimers disease, obesity, and others, is among the key factors impacting the growth of gene editing tools market. Cancer is registered to be the second most prominent cause of death worldwide. According to the World Health Organization (WHO), the number of deaths due to cancer worldwide in 2015 was 8.8 million. However, cancer alone was responsible for an estimated 9.6 million deaths globally in 2021.

Worldwide, approximately about 1 in 6 deaths occur owing to cancer. An analysis states that approximately 70% of deaths due to cancer occur in low- and middle-income countries. Thus, gene editing is most preferred for the management of rare genetic disorders, which is driving the demand for gene editing, thus generating a favourable revenue opportunity for gene editing tools.

The growing prevalence and incidence of rare genetic disorders, majorly Sickle Cell Disease (SKD), cancer, and Alzheimers disease, is leading to the high demand for genome editing, and is one of the leading factors that is contributing significantly to the growth of the gene editing tools market. Moreover, gene editing tools, such as CRISPR, TALENs, and ZFNs, find precise applications in the treatment of cancer. Owing to the high efficiency and accuracy of the CRISPR-Cas9 gene editing technique, it has emerged as a potential tool for cancer therapy. Among its various applications, CRISPR-Cas9 has a high clinical potential to detect novel target genes for cancer therapy.

To remain ahead of your competitors, request for a sample https://www.futuremarketinsights.com/reports/sample/rep-gb-9544

Biomedical Community Eyes Potential Application of Gene Editing Tools

Introduction of technologically advanced gene editing tools is expected to boost the growth of gene editing tools market. Recent advancements in CRISPR gene editing tools and their ease of use have generated significant interest in the biomedical community. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene editing has high potential to cater to the therapeutic landscape of induced disorders, owing to the presence of key players in the industry such as Intellia, CRISPR Therapeutics, and Editas. CRISPR gene editing tools offer precise gene-targeted treatments for -thalassemia and SKD. Among gene editing tools, there are potential applications for CRISPR in the gene editing tools market in human therapeutics as well as veterinary therapeutics.

Regional Players Focusing on Product Reach & Connectivity

North America, followed by Europe, is a prominent region in the global gene editing tools market. North America accounts for a revenue share of about 25.0% in 2021 in gene editing tools market. Europe accounting for the second-largest revenue share, and is followed by South Asia in the gene editing tools market. India, China, and Japan are among the emerging markets in the gene editing tools market. Japan is among the fastest-growing emerging markets in the global gene editing tools market, and is projected to grow at a CAGR of more than 6% during the forecast period of 2022-2028.

The gene editing tools market report tracks some of the key companies operating in gene editing tools market, such as Thermo Fisher Scientific Inc., ERS Genomics, CRISPR THERAPEUTICS, Merck KGaA, Editas Medicine, Takara Bio USA, New England Biolabs, Intellia Therapeutics, Inc., and GenScript Biotech Corporation. Majority of the key regional players in the gene editing tools market are focused on increasing their product reach and connectivity with the help of domestic distributors of gene editing tools. Moreover, the manufacturers of gene editing tools are focused to strengthening their businesses in high-growth markets, such as India, Japan, China, and Argentina, by expanding their sales and distribution channels across these countries.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert https://www.futuremarketinsights.com/ask-question/rep-gb-9544

Gene Editing Tools Market by CategoryBY Product:

BY Application:

BY End User:

Read the rest here:
Gene Editing Tools Market size is estimated to total US$ 1.6 Billion by 2029 - Digital Journal

When we talk about Cathie Wood stocks, were referring to the picks made by one of the top investors during the pandemic years.

Her flagship ARK Innovation ETF generated more than 150% returns for its stockholders and continued climbing for the better part of last year.

Cathie Woods ETFs have experienced some major losses in the latter half of 2021. From October to December last year, her fund lost more than $8 billion in value.

Her funds primarily hold disruptive stocks which can experience massive gains and losses, and there are many with incredible long-term cases. However, she seems unfazed by developments and has doubled down on her bets.

Investors continue to have faith in the star stock pickers abilities despite the lackluster performance. For example, these three Cathie Wood stocks that offer amazing upside potential.

Crispr Therapeutics(NASDAQ:CRSP)is a speculative biotech stock working on gene-editing technology.

The company hopes to make this technology the norm for disease treatment. Multiple therapies are in the trial stage and studied for various conditions, including diabetes, cancer, and other diseases.

The business currently generates minimal revenue as its products arent commercialized yet. Its market valuation is based purely on its fundamentals. CRSP is a disruptor, and most investors are banking on its long-term ability to surprise the market. However, it is likely to have a rocky road ahead involving regulatory hurdles and clinical trials.

The company has the opportunity to become market-leading biotech in treating serious diseases. If it can effectively achieve its objectives, then it will establish a strong moat, and it could grow into its massive $4.5 billion value.

Block(NYSE:SQ), formerly called Square, is a fintech giant boasting an incredible track record of growing revenues.

It launched as a payments solution which quickly became popular with small enterprises. It expanded into personal banking, transfers, and other profitable verticals, attracting millions of new users.

Its sales have grown more than 63% in the past five years.

SQ stock shed more than 58% in the past year as a result of the broader tech sell-off. Nevertheless, its underlying business boasts robust fundamentals and a strong growth runway ahead.

Its consumer and seller ecosystems are remarkably popular in the younger demographic. Additionally, its focus on emerging technologies such as blockchain is starting to pay dividends and could set it apart from its competition.

The companys revenue rose 86% last year, meaning its business will faces tough comparisons in the upcoming quarters. However, to expect the phenomenal growth to continue from the pandemic years is wishful thinking from investors.

Block will continue firing as its ecosystems further penetrate its target markets. Moreover, investments in other profitable areas will add a new direction to its business.

Teladoc Health(NASDAQ:TDOC) is a leader in virtual health care and has been developing a moat with its tremendous services ecosystem.

The telehealth specialist was a pandemic darling; however, its shares have fallen off a cliff since February of last year. It has shed off its frothy valuation and now presents itself as an attractive long-term investment.

The companys top line grew a spectacular 86% from the previous year to $2 billion. The business is still unprofitable, but there was a healthy improvement in this department last year.

Its loss per share came in at $2.73 per share compared with a loss per share of $5.36 in 2020. The telemedicine markets massive opportunities and competitive edge will help the business rake in consistently growing revenues and turn a profit soon.

Fortune Business Insights estimates that the global Telehealth market will likely grow at a tremendous 32%, from $90 billion in 2021 to a whopping $640 billion in 2028.

Moreover, the company estimates that around 92 million of the 298 million insured Americans have access to a Teladoc product. There is massive upside potential with Teladoc and this sell-off makes it an attractive buy at current levels.

On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines.

Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelors of science degree in applied accounting from Oxford Brookes University.

Read the original post:
3 Cathie Wood Stocks to Count on in Q2 - InvestorPlace

The Most Up To Date Market Insights And Analysis Performed In The PersuasiveCRISPR Gene Detection And Diagnostic Business Reportbrings marketplace clearly into focus. Businesses get highly benefited with the different segments covered in the market research report which provides better market insights to them with which they can drive the business into right direction. Under market segmentation topic of this report, research and analysis is done based on application, vertical, deployment model, end user, and geography. Depending on clients demand, huge amount of business, product and market related information has been brought together with CRISPR Gene Detection And Diagnostic report that eventually helps businesses create better strategies.

Data Bridge Market Research analyses that theCRISPR Gene Detection And Diagnostic Marketto grow at a CAGR of 11.65% and to account USD 4,708.89 million by 2028 and in the forecast period of 2022-2028.

Download Free Exclusive Sample Report: To Know the Impact of COVID-19 on this Industry@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-crispr-gene-detection-and-diagnostic-market

Global CRISPR Gene Detection and Diagnostic Market research reportalso provides the latest manufacturing data and industry future trends, allowing you to identify the products and end users driving profits growth and productivity. The Market report lists the most important competitors and provides the insights strategic industry Analysis of the key factors influencing the market. The report includes the forecasts, investigation and discussion of significant industry trends, market volume, market share estimates and profiles of the leading industry Players. Global CRISPR Gene Detection and Diagnostic Industry Market Research Report is providing exclusive vital statistics, information, data, trends and competitive landscape details.

The Segments and Sub-Section of CRISPR Gene Detection and Diagnostic Market are shown below:

By Type (Predictive & Presymptomatic Testing, Carrier Testing, Prenatal & New-born Testing, Diagnostic Testing, Pharmacogenomic Testing, Others)

By Disease (Alzheimers Disease, Cancer, Cystic Fibrosis, Sickle Cell Anaemia, Duchenne Muscular Dystrophy, Thalassemia, Huntingtons Disease, Rare Diseases, Other Diseases)

By Application (Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Others)

To Gain More Insights into the CRISPR Gene Detection and Diagnostic Market Analysis, Browse Summary of the Research Report@https://www.databridgemarketresearch.com/reports/global-crispr-gene-detection-and-diagnostic-market

COMPANIES MENTIONED INCLUDE (we can also add the other companies as you want.):

Abbott

Ambry Genetics

BD

Biocartis

BIO-HELIX

bioMerieux SA

Blueprint Genetics Oy

Cepheid

deCODE genetics

Illumina, Inc

Invitae Corporation

Luminex Corporation

..

No. of CRISPR Gene Detection and Diagnostic Market Report Pages: 350

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @https://www.databridgemarketresearch.com/toc/?dbmr=global-crispr-gene-detection-and-diagnostic-market

No of Figures: 60

The report also focuses on global major leading industry players of Global CRISPR Gene Detection and Diagnostic Market providing information such as company profiles, product picture and specification, price, capacity, cost, production, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.

CRISPR Gene Detection and Diagnostic MarketScenario

CRISPR basically identifies unique genetic material instantly and accurately. This technology is cheaper, reliable and accurate than of previous DNA editing techniques.

Increased funding by government and market players for gene editing technologies in the forecast period are the major factors that will influence the growth of CRISPR gene detection and diagnostic market. Furthermore, rise in the numbers of clinical trials and research & development activities for treatment of various diseases are the driving factor accelerating the growth of the CRISPR gene detection and diagnostic market.

Rising innovations and adoption and constant competition among the existing players has led to technological development and advancement in the technology which leads to further provide beneficial opportunities for the CRISPR gene detection and diagnostic market growth.

Global CRISPR Gene Detection and Diagnostic Market Scope and Market Size

The CRISPR gene detection and diagnostic market market is segmented on the basis of type, disease and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of type, the genetic testing market is segmented into predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing and others.

Based on disease, the genetic testing market is segmented into Alzheimers disease, cancer, cystic fibrosis, sickle cell anemia, duchenne muscular dystrophy, thalassemia, huntingtons disease, rare diseases, and other diseases.

Based on application, the genetic testing market is segmented into cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others.

Historical year 2010-2018; Base year 2019; Forecast period- 2022 to 2028 [** unless otherwise stated]

The countries covered in the CRISPR Gene Detection and Diagnostic market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: CRISPR Gene Detection and Diagnostic Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: CRISPR Gene Detection and Diagnostic Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Complete Report Details with Table of Content and Figures@https://www.databridgemarketresearch.com/reports/global-crispr-gene-detection-and-diagnostic-market

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

See the article here:
CRISPR Gene Detection and Diagnostic Market 2022-Global Industry Size, Share, Forecasts Analysis, Company Profiles, Competitive Landscape and Key...

Well-worn variations of the saying, busier than a, realistically capture how cow/calf producers feel during day-to-day management of their female herd. Consideration of how and whether or not bovine in vitro fertilization (IVF) will fit and bring success to their cattle breeding plans is often dismissed as impossible for numerous reasons.

Operations strive for accelerated genetic progress, but advancement is often hampered by rigid timelines of conventional embryo flushing or limitations of follicle stimulating hormone (FSH) deliveries.

Bruno Sanches, Vytelles VP of Operations, believes plans no longer need to follow this outdated pattern.

At Vytelle, our process is very attractive and accessible for all operations, he says. With our hormone free bovine in vitro fertilization program, any customer can access our cutting-edge technology simply by bringing their selected female donor to one of our satellite locations. She doesnt need any preparation or labor associated pre-oocyte collection. Its the most accessible, reliable and predictable way of using IVF.

Producers can research the best fit for their donor needs and access hormone-free IVF services at several locations scattered throughout the country. Without a hormone treatment protocol, oocyte collections can be performed from the same donor on a weekly basis allowing those with limited numbers time to build a well-stocked frozen embryo bank before breeding season.

The speed of genetic progress by quickly multiplying offspring from elite performing animals and shortening generation intervals through reproductive efficiency can be improved exponentially using four basic IVF tips.

Ensure Nutrition Management of Donors and Recipients

First, for producers to ensure the highest success rates to accelerate their herd, Sanches explains nutrition and management are key as they directly impact the oocyte quality and collection capabilities of donors and effectively support embryo transfers (ET) in recipients.

If we dont have a good egg, we cant make the quality embryos a customer expects, he said. Using accurate nutrition practices meeting energy, crude protein, mineral and vitamin requirements is critical for consistent follicular growth and oocyte quality.

He urges producers to begin stabilizing their donors nutrition levels early, at least 60 to 90 days prior to breeding season as correcting deficiencies and building oocyte quality and embryo development takes time.

Likewise, recipients must also be suitably maintained to create a successful embryo transfer.

He suggests working with a nutritionist to assess condition and develop proper rations supportive of lactation requirements and post-calving needs, preferably at least 30 days prior to ET for strong synchronization responses and pregnancy success.

They need to be in good shape to receive an embryo and carry through a productive pregnancy. At times, people mistakenly assume recipients arent as important and cut corners with nutrition. Then, we transfer an expensive embryo into them, and they lose money.

Optimize Collection Time Based off Breeding

Many producers believe IVF is limiting and difficult to keep on the right track, but Sanches explains hormone-free IVF expands rather than limits options.

Donor choice is extensive, ranging from prepubertal, as young as 6 months of age, to 15 days post-calving, plus pregnant females within the first 100 days of gestation. Additionally, without the need for FSH injections, producers can select donors and allow them to remain in their natural environment until the day of collection.

Sanches adds with such a wide range of availability, producers can focus on collecting from their elite donors, while ensuring their reproduction goals, by storing frozen embryos pre-breeding-season to meet their expanded needs. During breeding season, the producer can continue to collect from their donors and transfer fresh embryos into recipients and supplement with frozen embryos from their tank.

If we wait to collect embryos, transfers will be spread across an entire cattle breeding season. Many breeders prefer to start with all embryos transferred in the first few weeks. Then, recipients are released for natural service. I strongly suggest developing an embryo bank before breeding season so theres plenty to come out of the gate in good shape.

For those wanting to breed their donors, he recommends harvesting oocytes during the last collection, but leaving the most dominant follicles in the ovaries.

We know this egg will be ovulated, and she will breed successfully after a last collection. Its a natural process.

As producers realize they dont need to utilize IVF only on their problem or nonresponding cows; today, its become the first choice for their best animals. They can replicate the right genetics faster with hormone-free IVF rather than conventional flushing.

Capitalize on Post Breeding Opportunities

Sanches outlines oocyte collection doesnt need to end once a donor becomes pregnant.

Its an exciting aspect that we may begin using IVF again approximately 15 days after calving, 40 days post breeding and after a pregnancy confirmation, he said. Herd genetics are accelerated while keeping donors on track naturally, right up to 100 days of pregnancy. After confirmation, we can collect up to four more times before the fetus and the uterus drop out of reach.

He believes keeping donors on a regular schedule is important but admits everything is flexible and heavily dependent on a customers needs and numbers. He recommends collection every other week but the logistics of both donors and recipients need to be evaluated.

Planning ahead before cattle breeding season and having the donors on a schedule matching all the involved logistics is critical, he stressed. Know which satellite location will be used, where the embryos will be made and where the recipients are located. Donors and recipients might be in different states. We work with clients to understand their needs, explain our platform and help them be successful.

Pregnancy Checking and Live Calf Data

Once plans are in motion and oocytes have been collected, the fertilization process will take place in a laboratory. After eight days, viable embryos will be available for producers, fresh or frozen, depending on the producers request.

Producers can synchronize their receiving females to maximize the transfers possible in one day. Transfer services are commonly utilized; typically, IVF companies can provide or recommend a trusted partner.

Most US beef operations complete embryo placements early in the breeding season and follow up with natural service bulls. Sanches stresses its vital they work with their veterinarian to complete a pregnancy check.

If we dont confirm a pregnancy from an embryo or a bull, we cant track the due date, he said. The timing difference and due date will be around 15 to 25 days. If its not tracked, we may have calves overdue which can become a problem during the calving season. Ideally, we like to check at 45 and again at 90 days, but I encourage at least one check for reliable data to be gathered.

To optimize results with IVF embryos and help ensure the success of resulting calves, accurate record keeping should include pregnancy confirmation, gestation length, calf sex, birth weight and subsequent health status information.

Its a powerful technology but many people still have the misconception bovine in vitro fertilization is very expensive making it out of reach to progress their entire herds genetics, Sanches said. Some believe its time consuming, labor intensive and requires extensive preparation protocols. Its really a natural process with zero donor preparation. Plus, lastly, our customers love that they only pay for viable embryos. It changes the game for how breeders can use the technology.

Follow this link:
4 Tips to Include Bovine In Vitro Fertilization into Breeding Season - Drovers Magazine

Brainy Insights Pvt. Ltd.

Asia-Pacific is the greatest contributor in terms of veterinary artificial insemination market revenue due to rising demand for dairy and animal-based protein and government performance.

Pune, April 11, 2022 (GLOBE NEWSWIRE) -- As per the report published by The Brainy Insights, the global veterinary artificial insemination market is expected to grow from USD 4.74 billion in 2021 to USD 8.42 billion by 2030, at a CAGR of 6.6% during the forecast period 2022-2030.

The main advantage of artificial insemination is that it reduces the danger of disease transmission involved with animal reproduction. The need for high cow efficiency and milk composition is expected to rise due to artificial insemination. To address the ever-increasing demand, industry participants are employing synthetic insemination processes to generate high-quality cattle breeds and boost productivity. This factor is expected to grow the global veterinary artificial insemination market during the forecast period. Global population growth, urbanization, and an increase in the average population's purchasing power are all expected to enhance the production of high-quality dairy and allied goods. In the following years, the global veterinary artificial insemination market is likely to be driven by an increase in demand for high-quality dairy products.

Get a sample of the report from: https://www.thebrainyinsights.com/enquiry/sample-request/12681

The growing worldwide population and expanding need for animal-based protein drive the demand for artificial insemination in household farmed animals. Improving veterinarian services and increased animal healthcare costs are also urging market expansion. Moreover, the main businesses are forming strategic alliances to increase their range of animal genetics and boost their position in other sectors. The procedure of achieving conception withoutsperm or sperm in the female uterus is known as artificial insemination. Cattle are bred with freshly, uncooked, or cold straw of semen. Insemination is a method of obtaining pregnancy in animals using in vitro fertilization. It is also utilized in assisted reproduction and contraceptive innovations to allow animals to reproduce in heat. Veterinary artificial insemination is an excellent technological tool for enhancing animal heredity and production.

Story continues

Key players operating in the global veterinary artificial insemination market are:

Genus CRV URUS Group LP Viking Genetics SEMEX Swine Genetics International STgenetic Select Sires Inc. Stallion AI Services Ltd Shipley Swine Genetics

Enquire before purchasing this report at: https://www.thebrainyinsights.com/enquiry/buying-inquiry/12681

To enhance their market position in the global veterinary artificial insemination market, the key players are now focusing on adopting the strategies such as product innovations, mergers & acquisitions, recent developments, joint ventures, collaborations, and partnerships.

For example, Genus plc, a leading animal genetics firm, collaborated with Beijing Capital Agribusiness Co. Ltd, a prominent Chinese animal protein breeding firm, to investigate and produce virus-resistant procedures in pigs. For example, Elanco Animal Health established cooperation with Ducks Unlimited in April 2021 to promote sustainable development and agriculture - especially beef cattle development across North America. To fulfill the increased demand, LIC, an agritech co-operative established in New Zealand, will open a sexed sperm lab in the nation in September 2021.

In 2021, the swine type dominated the market with a market share of 22.12%.

The animal type segment is divided into cattle, equine, sheep, swine, canine, and others. In 2021, the swine type dominated the market with a market share of 22.12% and market revenue of 1.04 billion. The expanding output of organic pig meat due to increased animal welfare awareness will offer momentum to the industry. The rising demand for high-quality hog meat has compelled producers to expand their production facilities, which will benefit the market. Customers' increasing use of pig meat in various forms like ham, ham, steaks will allow the industry to expand quickly. The increasing popularity of pork in Western European countries will increase swine commerce and production in the near future.

In 2021, normal semen accounted for the largest share of the market, with 56.7%.

The product segment is divided into sexed semen and normal semen. In 2021, normal semen accounted for the largest share of the market, with 56.7% and market revenue of 2.68 billion. This growth is due to the low cost of normal sperm and the firm conception and low death rates.

The veterinary clinics accounted for the largest share of the market, with 37.3% for veterinary artificial insemination in 2021.

The end-user segment is divided into veterinary clinics, veterinary hospitals, others. The veterinary clinics accounted for the largest share of the market, with 37.3% and market revenue of 1.76 billion for veterinary artificial insemination in 2021. Clinics often provide wellness checks concentrating on preventative treatment and routine checkups for pets.While they can undertake spaying and neutering operations, they will need to send out more complicated cases to a better-equipped institution. They will have treatments and medicines, but they may not be as well-stocked as a vet clinic.

To purchase research report: https://www.thebrainyinsights.com/buy-now/12681/single

Regional Segment Analysis of the Veterinary Artificial Insemination Market

North America (U.S., Canada, Mexico) Europe (Germany, France, U.K., Italy, Spain, Rest of Europe) Asia-Pacific (China, Japan, India, Rest of APAC) South America (Brazil and Rest of South America) The Middle East and Africa (UAE, South Africa, Rest of MEA)

Among all regions, the Asia Pacific region emerged as the largest market for the global veterinary artificial insemination market, with a market share of around 38.14% and 1.08 billion of the market revenue in 2021. Due to several significant players in this region, Asia-Pacific is the greatest contributor in terms of market revenue. This is due to rising demand for dairy and animal-based protein and government performance, which is driving market expansion in this area.

About the report:

The global veterinary artificial insemination market is analyzed based on value (USD Billion). All the segments have been analyzed on a worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each piece. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining critical insight into the market. The study includes porter's five forces model, attractiveness analysis, raw material analysis, supply, demand analysis, competitor position grid analysis, distribution, and marketing channels analysis.

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash DHead of Business DevelopmentPhone: +1-315-215-1633Email: sales@thebrainyinsights.com Web: http://www.thebrainyinsights.com

See more here:
Veterinary Artificial Insemination Market to Reach USD 8.42 Billion by 2030; Increasing Government Initiatives, Technological Advancements, and...

A family in Esko, Minnesota, USA, has achieved a record that not many can measure up to - quite literally!

Meet the Trapp family of five; Scott, Krissy, Savanna, Molly, and Adam.

On 6 December 2020, the Trapps were confirmed as the tallest family in the world with an average height of 203.29 cm (6 ft 8.03 in).

The family's combined height is equal to the length of half a tennis court!

The youngest (but certainly not the smallest) member of the family is 22-year-old Adam Trapp, who towers over his siblings and parents at an astounding 221.71 cm (7 ft 3 in) tall.

Savanna Trapp-Blanchfield, 27, is next, measuring in at203.6 cm (6 ft 8 in). Last is their sister Molly Steede, 24, standing at 197.26 cm (6 ft 6 in) tall.

Unsurprisingly, all three Trapp kids played sports throughout their lives and were recruited by colleges for either basketball or volleyball.

"Coaches always said to us 'you can't teach height. Youre either tall or youre not,'" said Molly.

Although they have many tall extended family members, its clear that the Trapp kids followed in their parents' (very large) footsteps.

Krissy, their mom, comes in as the shortest among the Trapp family at 191.2 cm (6 ft 3 in), while the father, Scott, is a towering 202.7 cm (6 ft 8 in).

"I love saying that Im the shortest person in the worlds tallest family." Krissy Trapp

Measuring up to such a record-breaking achievement was a tall task. Savanna credits her "super tall, little brother," Adam, for inspiring her to reach out to Guinness World Records.

In December 2020, the family went to Dr. Anna Sudoh, an orthopaedics doctor at Essentia Health, to be measured.

Each family member had to be measured three times throughout the day, both standing up and lying down. This average of these measurements is used to calculate their height.

After meeting all the criteria to qualify for a place in the record books, the Trapps were thrilled to learn they had become the new title holders.

"My sister called the family up to tell us that we officially got the record. Everyone was excited about it, and it was almost hard to believe, said Adam.

The family feels that the worldwide recognition theyve received makes up for the downside of being so tall.

"Our friends and family are so proud of us and like to use us for bragging rights, saying they know a world record holder," said Savanna.

Qualifying to be recognized as the tallest family certainly came along with some growing pains, both literally and figuratively.

"I have always been tall but had a growth spurt where I grew an inch and a half in one month." Savanna Trapp-Blanchfield

"The growing pains were unreal. I have stretch marks on the back of my legs, Savanna continued.

The Trapps each realized they were unusually tall early on, constantly standing out among their peers.

When I was in the first grade, I was taller than my teacher, said Scott.

But whats it like to look down at everyone you meet?

It's a dilemma this super-tall family understands all too well. The Trapps have grown used to the frequent comments and stares they get in public.

Being taller than nearly everyone they meet, except for the occasional basketball player, means the family attracts attention everywhere they go.

They have learned to embrace their genetics and use their height as a way of engaging in conversations and educating others.

"Being able to meet new people when they come up and ask me questions about my height is something I like the most," said Adam.

The Trapps also encounter trying situations that most average-sized individuals dont even have to think about.

"If I stand up too fast, Ill faint and its a long way to fall," Savanna joked.

Besides having to duck to get through doorways, frustrating shopping experiences and difficulties driving a car because of their long legs, the Trapps agree that their spectacular size brings far more ups than downs.

"My height is useful for household projects. I dont ever need a ladder." Scott Trapp

Aside from their incredible accomplishment, the Trapps are just the same as any other family.

"I still put on my pants one leg at a time like most people. They're just really long pants," said Adam.

The family loves being able to share their most unique characteristic, which they feel has made them a strong family unit.

Since they can each relate to the trials and tribulations that come along with their stature, the Trapps often lean on each other for support.

"Its nice to have a shoulder thats tall enough for you to lean on. Who better to understand what youre going through than the people who are even taller than you are?" Molly Steede

The Trapp family hopes to continue using their height to their advantage.

While Savanna dreams of eventually pursuing acting, modelling, or breaking the record for the largest hands on a living person (female), Molly is looking forward to one day starting her very own tall family.

The Trapps hope that their record-breaking tallness will empower others who are unique or feel different.

They want the world to know that any one attribute shouldnt define you and encourage people to judge others by who they are deep down inside rather than what they look like.

"There is joy and freedom in embracing who you are," said Savanna.

"Rock what you got. There is nobody else like you and that is fantastic."

Go here to read the rest:
Minnesota family confirmed as tallest in the world - Guinness World Records

Patient recruitment

In this study, a total of 96 EGC patients (TNM classification: T1A) who were subjected to ESD treatment were recruited and their expression of circFNDC3B was measured for grouping. Subsequently, the median circFNDC3B expression was calculated and utilized as the indicator to divide the patients into a Low expression group (N=48, including all EGC patients whose expression level of circFNDC3B was at or above the median expression of circFNDC3B) and a High expression group (N=48, including all EGC patients whose expression level of circFNDC3B was below the median expression of circFNDC3B). Therefore, for further analysis, since the patients were grouped according to their median, there are same number of patients in each group. The demographic and clinic parameters of both patient groups, including their sex, age, BMI, status of H. pylori infection, history of alcohol abuse and smoking, tumor site, as well as clinical grade of ESD was collected by reviewing their medical records, carrying out breath test for H. pylori infection, serological examinations, as well as bacterial culture, and the demographic and clinic parameters of the two patient groups were compared using Students test. In this study, ESD was defined as a type of adenocarcinoma constrained to the mucosa tissues or submucosa tissues in the stomach. All subjects with a past ESD history or those who received treatment for multiple ESD were not enrolled. An endoscopic forceps biopsy operation was carried out in each patient to collect ESD tissue samples for subsequent Western blot, qPCR and IHC assays. ESD follow-ups were carried out 2, 3, 6, 9, 12, 24, as well as 36months after the initial ESD operation. The level of gastric atrophy was assessed using histological evaluation results based on the endoscopic atrophy border scale developed previously (Kimura et al. 1969; Ito et al. 1996; Satoh et al. 1996). Institutional ethical committee of Chinese PLA NO.254 Hospital has approved the protocol of this study. All methods were performed in accordance with the last vision of the Declaration of Helsinki. Written informed consent was obtained from all patients before the study.

In this study, MKN28 cells, a extensively-studied gastric tubular adenocarcinoma cell line which were established from a 70-year-old female patient, were used to carry out cellular experiments. In brief, MKN28 cells were acquired from American Type Culture Collection (ATCC, Manassas, VA) and cultured according to the recommended conditions provided by the manufacturer, i.e., the cells were cultured in a Roswell Park Memorial Institute 1640 (RPMI 1640) medium (Gibco, Thermo Fisher Scientific, Waltham, MA) supplemented along with 10% of fetal bovine serum as well as 1% of penicillin and 100 U/ml of streptomycin. The culture conditions were 37C, 5% CO2 and saturated humidity. Furthermore, all cells were regularly examined to affirm the absence of Mycoplasma. When the cells reached 70% confluence, they were sub-cultured and divided into different groups. In cell model I, the MKN28 cells were divided into 2 groups, i.e., 1. pGL group (MKN28 cells transfected with an empty plasmid); and 2.pGL-FNDC3B group (MKN28 cells transfected with a pGL3 plasmid inserted with the circFNDC3B fragment). In cell model II, the MKN28 cells were also divided into 2 groups, i.e., 1. NC siRNA group (MKN28 cells transfected with a scramble negative control NC siRNA); and 2.pGL-FNDC3B group (MKN28 cells transfected with circFNDC3B siRNA to silence the expression of circFNDC3B). In cell model III, we utilized the MKN28 cells to establish a H. pylori-infected gastric cancer cell model in comparison with un-infected cell model. The MKN28 cell were established as 2 groups, i.e., 1. Control group (MKN28 cells in unprocessed medium); and 2. rTip- group (MKN28 cells cultured in medium containing 12.5g/mL rTip-).

According to protocols provided by a previous publication22, to obtain rTip-, we transfected Tip- into Escherichia coli for subsequent amplification. And the amplified rTip- was purified for subsequent cell model establishment. All transfections were carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the recommended transfection conditions provided by the manufacturer, and the transfected cells were harvested 48h after the start of transfection to analyze the expression of target genes.

The harvested cell as well as tissue samples were treated by utilizing a miRCURY RNA Isolation Kit (Exiqon, Qiagen, Germantown, MD) according to the recommended assay methods provided by the assay kit manufacturer to isolated cellular RNA. Then, the isolated RNA was assayed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Mountain View, CA) in conjunction with an RNA 6000 Pico assay kit (Agilent Technologies, Mountain View, CA) according to the recommended assay methods provided by the assay kit manufacturer to quantify the RNA concentration. In the next step, 1g of isolated total RNA was converted into cDNA by making use of a QuantiTect Reverse Transcription assay kit (Qiagen, Germantown, MD) according to the recommended assay methods provided by the assay kit manufacturer. Finally, real time quantitative polymerase chain reaction (RT-qPCR) was performed on a BX-384 real time PCR apparatus (Bio-Rad laboratories, Hercules, CA) by making use of a QuantiTect SYBR Green PCR assay kit (Qiagen, Germantown, MD) according to the recommended assay methods provided by the assay kit manufacturer to evaluate the relative expression of circFNDC2B, miR-942, miR-510, CD44 mRNA as well as CDH1 mRNA in each sample using the 2Ct approach. The expression of GAPDH in each sample was used as the internal control.

We utilized online bioinformatic tools including TargetScan (http://www.targetscan.org/vert_80/) and miRDB (http://mirdb.org/) to compare the sequences of circFNDC2B, miR-942, miR-510, CD44 mRNA and CDH1 mRNA. Accordingly, we detected a putative binding site of miR-942 on circFNDC3B, while a putative binding site of miR-942 was detected on the 3UTR of CD44 mRNA. Similarly, we detected a putative binding site of miR-510 on circFNDC3B, while a putative binding site of miR-510 was detected on the 3UTR of CDH1 mRNA. In the next step, we performed luciferase assays in MKN28 cells to confirm the regulatory relationship of circFNDC2B/miR-942, circFNDC2B/miR-510, miR-942/CD44 mRNA, and miR-510/CDH1 mRNA. In brief, the wild type sequences of circFNDC2B, CD44 mRNA, and CDH1 mRNA containing the corresponding miRNA binding sites were cloned into pGL plasmid vectors to generate wild type plasmids of circFNDC2B, CD44 mRNA, and CDH1 mRNA. At the same time, the sequences of circFNDC2B, CD44 mRNA, and CDH1 mRNA containing the corresponding miRNA binding sites were subject to site-directed mutagenesis to generate mutant type sequences of circFNDC2B, CD44 mRNA, and CDH1 mRNA containing the corresponding miRNA binding sites, which were also cloned into pGL plasmid vectors to generate mutant type plasmids of circFNDC2B, CD44 mRNA, and CDH1 mRNA. In the next step, MKN28 cells were co-transfected with the plasmids carrying wild type or mutant type circFNDC2B, CD44 mRNA, and CDH1 mRNA along with miR-510 and miR-942. At 48h post transfection, the luciferase activity of transfected cells was assayed by utilizing a GloMax Multi Detection assay kit (Promega, Madison, WI) according to the recommended assay methods provided by the assay kit manufacturer.

The recurrence-free rate of the patients was analyzed by using R statistical software (version 3.0). The recurrence-free rate in each group was calculated at various follow-up time points, and the recurrence-free rates of the two groups were compared at the level of statistical significance of 0.05. The KaplanMeier survival curves were generated for high and low groups of circFNDC3B expression.

Cells as well as tissue samples were first lysed in a phosphatase- and protease-inhibitor containing 1X RIPA buffer (Thermo Fisher Scientific, Waltham, MA) according to the recommended assay methods provided by the assay kit manufacturer. The collected lysates were then centrifuged to collect proteins in the supernatant, whose concentration of total proteins was examined by using a BCA protein assay kit (Pierce, Thermo Fisher Scientific, Waltham, MA) according to the recommended assay methods provided by the assay kit manufacturer. In the next step, the protein in each sample was resolved by 10% SDS-PAGE and blotted onto nitrocellulose membranes (Hybond, GE Medical Care, Pittsburgh, PA), which was blocked with TBSS containing 5% of skim milk and subsequently incubated with primary anti-CD44 and anti-CDH1 antibodies as well as HRP-conjugated secondary antibodies in sequence according to the recommended antibody incubation conditions provided by the assay kit manufacturer (Abcam, Cambridge, CA). Finally, after the protein blots (all original protein blots are shown in Supplementary file) were developed by using an enhanced chemiluminescence Western blot substrate (Pierce, Rockford, IL) according to the recommended assay methods provided by the assay kit manufacturer, the relative protein expression of CD44 and CDH1 in each sample was calculated.

Collected tissue samples were paraffin embedded, sliced into 4 um sections, deparaffinized, gradient alcohol hydrated, and incubated with primary anti-CD44 antibodies and biotin-labeled secondary antibodies in sequence according to the recommended antibody incubation conditions provided by the assay kit manufacturer (Abcam, Cambridge, CA) to determine the positive protein expression of CD44 in each sample under a Zeiss Axioskop microscope.

Unless otherwise specified, all results are presented as meanS.E.M of 4 independent tests. Statistical evaluations were done by making use of the Student's t test in SPSS 21.0 software (IBM, Chicago, IL) and Prism 8.0 program (GraphPad, San Diego, CA), and P<0.05 was deemed as statistically significant.

View post:
The upregulation of circFNDC3B aggravates the recurrence after endoscopic submucosal dissection (ESD) in early gastric cancer (EGC) patients |...

One of the most popular characters in the Star Wars universe, Boba Fett was introduced theatrically in Star Wars: Episode V Empire Strikes Back. Not much was known about the masked character after the film was released, with fans becoming attached to the mysterious nature of the bounty hunter, and his glorious Mandarloian armor. The character has been a fan favorite throughout the years, but some fans waver on the characters popularity. Recently the character starred in his own Disney + series, The Book of Boba Fett which was met with mixed reviews.

It wouldnt be until Star Wars: Episode II Attack of the Clones that Star Wars fans would learn the truth about Boba Fetts origin with the controversial decision to make him a clone. Star Wars fans were outraged upon learning that Boba Fett had really been a clone the entire time, someone with the same origin as the stormtroopers who couldnt shoot straight, claiming that the origin ruined the character. But was Boba Fett really a clone like those who fought in the clone wars?

In Star Wars: Episode II Attack of the Clones, Obi-Wan Kenobi uncovered a secret, that a Jedi named Sifo-Dyas had employed a cloning facility on Planet Kamino, to create a clone army for the Republic. Kenobi was under the impression that Sifo-Dyas had been dead for years prior, and it was discovered later that he was killed by Count Dooku, so seemingly Darth Sidious had ordered the clone army. It was later revealed that all of these clones were made from a single specimen, a Mandalorian bounty hunter named Jango Fett.

The cloning facility had compensated Jango Fett quite well, paying him twenty million credits but he also requested one clone for himself, Boba Fett, in addition to his payment. The ordinary clones would be aged up to adulthood and also had their behavior modified which made them better soldiers by making them easier to control. Boba Fett, however, was not aged up and was only a child when Obi-Wan Kenobi met Jango Fett.

Boba Fett was a child when Jango was killed in the Battle of Geonosis by Mace Windu, so Jango had some time to teach the character his bounty hunting ways before he died. Because Jango requested that Boba be untampered with, Jango had made him entirely unique compared to any other clone made. Lets take a look at the few different types of clones we have seen throughout Star Wars and how Boba Fett differs from them.

As mentioned previously, all the Clone Troopers were conditioned to be soldiers and were easier to control. In addition to that, Boba Fett was not changed when Order 66 was launched. A large majority of the clones had a chip implanted in their head which, when activated by launching Order 66, the clones would suddenly turn on the Jedi, which they did in Star Wars: Episode III The Revenge of the Sith when Darth Sidious launched the order, which resulted in the Jedi Purge. Boba Fett did not have the chip implanted in him because of Jangos wish to raise him by himself, unaltered by the Kaminoans. Because he was unaltered, Boba Fett also aged naturally and would be older than the original Clone Troopers.

This first batch of clones were trained to be soldiers, whereas Boba Fett had to learn to be as good as Jango, even though he still had the same genetics. Boba was also more determined than the Clone Troopers throughout The Clone Wars as shown in Star Wars: The Clone Wars, as Boba Fett started his journey fueled by revenge. Boba attempted to assassinate Mace Windu for killing Jango Fett. He also ended up in prison and encountered many criminals which he would have learned from, such as Cad Bane and Asajj Ventress. The Clone Troopers rarely learned from one another, taking orders from the Jedi at first, then taking their orders from the Empire after Order 66. The Clone Troopers were also seen by some Jedi and the Empire as disposable, whereas there was only one Boba Fett.

Debuting in the final season of Star Wars: The Clone Wars, The Bad Batch was a group of clones who were deemed to be genetically altered. These clones all had some mutations which caused them to be proficient in different areas, therefore furthering their genetic differences from Boba Fett. These troopers were spun off into their own animated series on Disney + named Star Wars: The Bad Batch. Although Boba Fett is different from these clones, they are not regular clones either so this doesnt necessarily mean that Boba Fett is different from all clones, just that he is unique.

Introduced in Star Wars: The Bad Batch was the character called Omega, who surprisingly is quite similar to Boba Fett. Seemingly without Jango Fetts permission, the Kaminoans created a perfect genetic clone of Jango Fett who was female. Another thing that sets her apart from the other members of The Bad Batch and other clones is that she was not aged like the other clones, aging naturally like Boba Fett. She might be the one clone that is most like Boba Fett, genetically at least.

The main difference between Boba Fett and the clones who served in the Empire as stormtroopers is that they are different from the Clone Troopers who fought in The Clone Wars, especially those who appeared sooner in the original Star Wars trilogy. There was a percentage of stormtroopers who were not clones but the comparison between Boba Fett and the stormtroopers is only for those who were clones. The clones would either be quite old, having already been grown adults in The Clone Wars, or they would not be of the same genetic material as the Clone Troopers.

Either the stormtroopers were a copy of the Clone Troopers, therefore a clone of a clone and would be a worse soldier than the Clone Troopers and Boba Fett. Or they were mixed with other genetic material, lessening the impact of Jango Fetts. And as Jango Fett was considered one of the galaxys best bounty hunters this would be a disservice to the stormtroopers and would prove that Boba Fett was the superior specimen.

So there you have it, Boba Fett is technically a clone, but because of Jango Fett and his insistence that he have an unaltered, true copy of himself, he stands apart from the rest of the clone army. Many clones were created on Kamino but not all of them were the same, with Boba Fett and Omega being the outliers. Hopefully, the origins of the character do not sour your love for the character, as Boba Fett is still one of the coolest designed characters in the Star Wars universe.

Read this article:
Is 'Boba Fett' a Clone? - We Got This Covered

The research and analysis firm Datavagyanik has published the updated version of its report Detailed Analysis, Business Opportunities and Forecast of Plant Breeding and CRISPR Plants Market by Countries. The updated version of the report is released with the latest data, industry trends and competitive benchmarking. The report uses analytical models to study country-level market patterns and to make forecasts for the next ones during the time frame (2022-2030).

Request a free sample of the full report https://datavagyanik.com/market-intelligence-enquiry/

Insights Covered in the Report:

Plant Breeding and CRISPR Plants Market Sizing and Needs Analysis The needs analysis part of the Toilet Liner Spray for Toilet study provides details on actual market size as well as total addressable market (TAM) size at global and country level

Plant Breeding and CRISPR Plants Market Forecast : Actual market data has been provided for year 2021 and forecast from 2022 to 2030 has been covered. The seven year market forecast has been covered in the study.

Customer Pain Points: Pain points and scope of innovation are one of the key components of this study. There are certain areas that industry participants need to understand in order to excel. As competition increases, it is very important to have a competitive advantage.

Comparing Supply and Demand: Understanding the dynamics of supply and demand is important for working on future business strategies and action plans. This is also important for product development and pricing decisions. Added value to this market study of toilet spray.

Future prospects for the market The market is constantly evolving and the study highlights future expectations and associated strategic views.

Key Market Trends Plant Breeding and CRISPR Plants market report analyzes major market trends which will impact the Plant Breeding and CRISPR Plants market in the future. The long-term and short-term implications of these factors have been presented to help decision makers understand the industry at a granular level.

Industry Challenges There are industry challenges that must be addressed in order to be successful in the Plant Breeding and CRISPR Plants business. Companies in the Plant Breeding and CRISPR Plants market face these challenges. The companies were analyzed with regard to product portfolio, target customers, turnover and strategic business decisions.

Investment Opportunities Emerging business segments and revenue streams have been identified to help industry participants plan their revenue mix and plan their investment strategies.

Request a free sample of the full report https://datavagyanik.com/market-intelligence-enquiry/

Detailed Global and Country Level Analysis: Global and country level analysis has been covered in the report.

The regions covered in the Plant Breeding and CRISPR Plants study are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. and Canada.

The Plant Breeding and CRISPR Plants Europe region includes the analysis of Germany, France, Italy, Spain, the UK and the rest of Europe.

Plant Breeding and CRISPR Plants Asia Pacific includes analysis of China, India, Japan, South Korea, Indonesia, Australia and the rest of Asia Pacific.

Plant Breeding and CRISPR Plants Rest of World (Latin America, Middle East, Africa). The report on Bathroom Coating Spray Market encompasses an in-depth analysis of ongoing technological advancements and developments and also provides the market revenue forecast for the period (2021-2030).

In addition, the report provides country-level analysis. To help strategic decision makers, It includes a competitive landscape to measure the market competition based on various factors such as drivers, restraints and opportunities. Key questions answered by this study

How big was the Plant Breeding and CRISPR Plants market in historical years

How will the Plant Breeding and CRISPR Plants market grow in forecast years i.e. from 2022 to 2030? What is the annual growth rate?

Who are the key target audiences for the Plant Breeding and CRISPR Plants market?

Derivative analysis through consumption and spending perspective.

Micro and macro factors in Plant Breeding and CRISPR Plants?

Internal and external variables in Plant Breeding and CRISPR Plants?

Purchasing power from the point of view of the end consumer.

What marketing techniques should a company use to promote its brand, product or service?

What will the future market drivers, constraints and opportunities look like? An impact on market dynamics and analysis supporting current market trends?

Which segment and region are driving the market growth and how?

Which are the main countries actively contributing to the development of the market?

What would be the market size of each segment in the main countries, which in turn are responsible for generating income for each region?

Who are the visionaries, leaders, challengers and market niches? Which Players in the Plant Breeding and CRISPR Plants Market?

Strategic initiatives by Plant Breeding and CRISPR Plants market players and their impact on market growth.

Which goals have to be mapped

Purchase the full report at https://datavagyanik.com/reports/market-intelligence-report-trends-competevive-analysis-future-projections2022-2030/

Contact us:

Atul B (Sales Head)

Phone: +1 551 226 6002

Website: https://datavagyanik.com/

Email: [emailprotected]

See the original post:
Plant Breeding and CRISPR Plants Market Competitive Analysis, New Trends and Forecasts (2022-2030) Political Beef - Political Beef

New Jersey, USA,-The global Crispr And Crispr Associated Genes Market is comprehensively and in-depth examined in the report, focusing on the competitive landscape, regional growth, market segmentation and market dynamics. For the preparation of this comprehensive research study, we have used the latest primary and secondary research techniques. The report provides Porter's five forces analysis, tappet analysis, competitive analysis, manufacturing cost analysis, sales and production analysis, and various other types of analysis to provide a complete overview of the global Crispr And Crispr Associated Genes market. Each segment of the global Crispr And Crispr Associated Genes market is carefully analyzed on the basis of market share, CAGR and other important factors. The global Crispr And Crispr Associated Genes market is also presented statistically with the help of annual growth, CAGR, sales, production and other important calculations.

We can customize the report to your liking. Our analysts are experts in Crispr And Crispr Associated Genes market research and analysis and have in-depth experience in customizing reports, having served tons of clients so far. The main objective of the preparation of the research study is to inform you about future challenges and opportunities of the market. The report is one of the best resources you can use to secure a strong position in the global Crispr And Crispr Associated Genes market.

Get | Download Sample Copy with TOC, Graphs & List of Figures@https://www.marketresearchintellect.com/download-sample/?rid=202013

Our report contains current and latest market trends, market shares of companies, market forecasts, competition benchmarking, competition mapping and an in-depth analysis of the most important sustainability tactics and their impact on market growth and competition. To estimate quantitative aspects and segment the global Crispr And Crispr Associated Genes market, we used a recommended combination of top-down and bottom-up approaches. We examined the global Crispr And Crispr Associated Genes market from three key perspectives through data triangulation. Our iterative and comprehensive research methodology helps us to provide the most accurate market forecasts and estimates with minimal errors.

The major players covered in Crispr And Crispr Associated Genes Markets:

Crispr And Crispr Associated Genes Market Breakdown by Type:

Crispr And Crispr Associated Genes Market breakdown by application:

As part of our quantitative analysis, we have provided regional market forecasts by type and application, market sales forecasts and estimates by type, application and region by 2030, and global sales and production forecasts and estimates for Crispr And Crispr Associated Genes by 2030. For the qualitative analysis, we focused on political and regulatory scenarios, component benchmarking, technology landscape, important market topics as well as industry landscape and trends.

We have also focused on technological lead, profitability, company size, company valuation in relation to the industry and analysis of products and applications in relation to market growth and market share.

Get | Discount On The Purchase Of This Report @https://www.marketresearchintellect.com/ask-for-discount/?rid=202013

Crispr And Crispr Associated Genes Market Report Scope

Regional market analysis Crispr And Crispr Associated Genes can be represented as follows:

This part of the report assesses key regional and country-level markets on the basis of market size by type and application, key players, and market forecast.

The base of geography, the world market of Crispr And Crispr Associated Genes has segmented as follows:

For More Information or Query or Customization Before Buying, Visit @ https://www.marketresearchintellect.com/product/crispr-and-crispr-associated-genes-market-size-and-forecast/

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations in addition to the objective of delivering customized and in-depth research studies.We speak to looking logical research solutions, custom consulting, and in-severity data analysis lid a range of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages. Etc Our research studies assist our clients to make higher data-driven decisions, admit push forecasts, capitalize coarsely with opportunities and optimize efficiency by bustling as their belt in crime to adopt accurate and indispensable mention without compromise.Having serviced on the pinnacle of 5000+ clients, we have provided expertly-behaved assert research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony, and Hitachi.

Contact us:Mr. Edwyne FernandesUS: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Website: https://www.marketresearchintellect.com/

Read more here:
Crispr And Crispr Associated Genes Market Size and Forecast (2022-2030) By Top Keyplayers | Thermo Fisher Scientific, Editas Medicine, Caribou...

Editas Medicine, Inc.

Marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient

Company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022 and expects to initiate dosing of the pediatric high-dose cohort this year

CAMBRIDGE, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the administration of EDIT-101, an experimental CRISPR gene editing medicine, to the first pediatric patient enrolled in the BRILLIANCE clinical trial, which is designed to test the safety of EDIT-101 for the treatment of Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder. This marks the worlds first in vivo, or inside the body, dosing of a pediatric patient with a CRISPR gene editing experimental medicine.

Administering the experimental medicine to the first pediatric patient in the BRILLIANCE trial marks a significant milestone toward delivering on the potential of CRISPR gene editing medicines being safe and effective in treating LCA10, which often results in significant vision loss and blindness early in life, said James C. Mullen, Chairman, President, and CEO, Editas Medicine. Currently, there are no approved treatments for LCA10, and we look forward to sharing future updates from the BRILLIANCE trial, including sharing additional clinical data, later this year.

Enrolling this first pediatric patient in the BRILLIANCE trial is an important step toward bringing potentially life-changing treatments to children with genetic retinal diseases. We are excited to be involved in research focused on testing potential new treatments for untreatable diseases like LCA10, said trial principal investigator for the site, Tomas S. Aleman, MD, the Irene Heinz-Given and John LaPorte Research Associate Professor at the Scheie Eye Institute of the Perelman School of Medicine at the University of Pennsylvania, and a retinal degeneration specialist with the Division of Pediatric Ophthalmology at Children's Hospital of Philadelphia (CHOP).

Story continues

Albert M. Maguire, MD, the F.M. Kirby Professor of Molecular Ophthalmology at Penn and a member of the Center for Advanced Retinal and Ocular Therapeutics, is the surgeon in the trial, in collaboration with Childrens Hospital of Philadelphia (CHOP), the nation's first hospital devoted exclusively to the care of children and the source of many breakthroughs and firsts in pediatric medicine. CHOPs Clinical In Vivo Gene Therapy (CIGT) program provided the clinical operations support to conduct the work at CHOP.

Editas Medicine initiated enrollment in the pediatric mid-dose cohort in the BRILLIANCE trial following the Independent Data Monitoring Committee (IDMC) endorsement based on an analysis of safety data from a clinical trial in adult patients that tested low-dose and mid-dose levels of the experimental medicine. The Company remains on track to complete testing of the pediatric mid-dose in the first half of 2022 and expects to initiate testing of the pediatric high-dose this year.

Previously, Editas Medicine completed dosing of all adult cohorts in its BRILLIANCE study and announced preliminary EDIT-101 clinical results demonstrated a favorable safety profile and encouraging signals of clinical benefit. The Company expects to provide a clinical update on the BRILLIANCE trial in the second half of 2022. The update is expected to provide safety and efficacy assessments on all adult patients who have had at least six months of follow-up evaluations, which will include at least 12 months of data on the adult mid-dose cohort, and at least six months of data on the adult high-dose cohort. Additionally, the Company is expanding enrollment in one or more of the previously completed adult cohorts to explore dose response and support establishment of registrational trial endpoints, which are anticipated by year-end.

About EDIT-101 EDIT-101 is a CRISPR/Cas9-based experimental medicine under investigation for the treatment of Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder. EDIT-101 is administered via a subretinal injection to reach and deliver the gene editing machinery directly to photoreceptor cells. EDIT-101 has been granted Rare Pediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration (FDA) and Orphan Designation from the European Medicines Agency (EMA).

About BRILLIANCEThe BRILLIANCE Phase 1/2 clinical trial of EDIT-101 for the treatment of Leber congenital amaurosis 10 (LCA10) is designed to assess the safety, tolerability, and efficacy of EDIT-101 in patients with this disorder. Clinical trial sites are enrolling up to five cohorts testing up to three dose levels in this open label, multi-center study. Both adult and pediatric patients (3 17 years old) with a range of baseline visual acuity assessments are eligible for enrollment. Patients receive a single administration of EDIT-101 via subretinal injection in one eye. Patients are monitored every three months for a year after dosing and less frequently for an additional two years thereafter. Additional details are available on http://www.clinicaltrials.gov (NCT#03872479).

About Leber Congenital AmaurosisLeber Congenital Amaurosis, or LCA, is a group of inherited retinal degenerative disorders caused by mutations in at least 18 different genes. It is the most common cause of inherited childhood blindness, with an incidence of two to three per 100,000 live births worldwide. Symptoms of LCA appear within the first years of life, resulting in significant vision loss and potentially blindness. The most common form of the disease, LCA10, is a monogenic disorder caused by mutations in the CEP290 gene and is the cause of disease in approximately 20-30 percent of all LCA patients.

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit http://www.editasmedicine.com.

Forward-Looking Statements This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, target, should, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Companys preclinical and clinical studies and its research and development programs, including completing dosing of the pediatric mid-dose cohort in the first half of 2022, initiating dosing of the pediatric high-dose cohort in the BRILLIANCE trial in 2022, and establishing registrational trial criteria by year-end 2022, and the timing for the Companys receipt and presentation of data from its clinical trials and preclinical studies, including a clinical update on the BRILLIANCE trial in the second half of 2022. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of the Companys product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Companys foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption Risk Factors included in the Companys most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

Continued here:
Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10 - Yahoo Finance

The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players associated withCRISPR and Cas Gene Market. The study also provides the dynamics that are responsible for influencingthe future status of the marketover the forecast period.

Click Here To get a Sample Report (Including Full TOC, Table & Figures)

https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

A detailed assessment of the value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies manufacturing CRISPR and Cas Gene, along with their product portfolios, enhances the reliability of this comprehensive research study.

Report Summary

The study offers comprehensive analysis on diverse features, including demand, product development, revenue generation, and sales of CRISPR and Cas Gene across regions.

A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account sales during the forecast period. Price point comparison by region with global average price is also considered in the study.

Connect To an Expert

https://www.factmr.com/connectus/sample?flag=AE&rep_id=4823

Regional analysis includes

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the CRISPR and Cas Gene Market during the forecast period.

Country-specific valuation on demand for CRISPR and Cas Gene Markets has been offered for each regional market, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

Need More Information about Report Methodology? Click here

https://www.factmr.com/connectus/sample?flag=RM&rep_id=4823

Research Methodology

In Fact.MRs study, a unique research methodology is utilized to conduct extensive research on the growth of the CRISPR and Cas Gene Market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the drawn conclusions.

Secondary resources referred to by analysts during the preparation of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of the research report as a primary resource.

Read More Trending Reports of Fact.MR:

http://www.globenewswire.com/en/news-release/2018/05/15/1502209/0/en/Fetal-and-Neonatal-Heart-Monitor-Market-Concerted-Efforts-to-Reduce-Preterm-Births-Driving-Adoption-in-Hospitals-and-Neonatal-Clinics.html

The Report Covers Exhaustive Analysis On:

The CRISPR and Cas Gene Market report offers detailed assessments and quantitative evaluations that shed light on numerous key aspects that have shaped its evolution over the historical period. In coming years, some of the key aspects that will shape the growth prospects during the forecast period are objectively covered in the study.

Explore Fact.MRs Comprehensive Coverage on Healthcare Landscape

Nano Healthcare Technology MarketForecast, Trend, Analysis & Competition Tracking Global Market Insights 2020 to 2030

Medical Suction Devices MarketForecast, Trend, Analysis & Competition Tracking Global Market Insights 2020 to 2030

Medical Grade Silicone Market Forecast, Trend, Analysis & Competition Tracking Global Market Insights 2020 to 2030

About Us:

Market research and consulting agency with a difference! Thats why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Oursales offices in United States and Dublin, Ireland. Reach out to us with your goals, and well be an able research partner.

Contact:

US Sales Office:11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E:sales@factmr.com

Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),Plot No: JLT-PH1-I3A,Jumeirah Lakes Towers,Dubai, United Arab Emirates

Originally posted here:
DNA-free Cas Genes Market is Expected to Witness Healthy Growth at 21.2% CAGR through 2026 Blackswan Real Estate - Blackswan Real Estate

The term genomics sounds quite interesting, although it is mainly confused with genetics. Genetics refers to the study of genes, whereas genomics is a broader term which encompasses the study of an organisms entire set of genes (genome).

Some facts to know

Do read: What is genetic engineering and how can it benefit healthcare?

Exploiting genomics in medicine

Genomic medicine is a speciality of medical science that uses an individual's genomic information to make diagnostic and therapeutic decisions. Some of the recent advances in genomic medicine are discussed below:

Image source: Vadimgozhda | Megapixl.com

Precision medicine

Precision medicine exploits an individual's genetic information for disease diagnosis and treatment. However, it doesn't only consider the genome but utilises other factors such as the environment of a person and their health history.

Precision medicine bypasses the 'one size fits all' approaches that are the same for everyone and develops individual-specific approaches.

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)

CRISPR is a gene editing tool and can be simply compared with a text editor, for a clear understanding. Also known as 'molecular scissors', the technique is used to edit genetic code. CRISPR shines a ray of hope in treating fatal diseases, including cancer and HIV.

Despite its great potential in medical science, the technique holds several apprehensions and questionable applications. Due to this reason, CRISPR is currently considered non-ethical in human beings and is banned in several countries, including the USA.

Gene therapy

Gene therapy involves the insertion of a healthy foreign genetic material into a person's cell to treat a disease. It is a one-shot cure as it corrects the underlying genetic cause of disease.

The first CAR T-cell-based gene therapy got approval in 2017 in the United States by the Food and Drug Administration (FDA). Gene therapies also hold a promising future for cancer treatment.

Concerns regarding gene-based techniques

Also read: Telix (ASX: TLX) adds new asset in its cancer treatment pipeline

Original post:
The role of genomics in medicine: A look at pros and cons - Kalkine Media

April 12, 2022

Given the state of the planet, is it OK to have a child? With so much grim climate news, can we allow ourselves to feel optimistic? If we talk with people from around the world, can we gain new insights on how climate change is affecting their lives?

These are some of the questions raised and answered by the winning writers of the first biennial Climate Narratives Prize, to be awarded at Arizona State University on April 22, Earth Day, at an event titled Hope, Alarm and Climate Change. Photo by iStock Download Full Image

The winners and two special mentions were selected from a collection of nominated works, exemplifying the best published narratives of the last five years that explore the reality and impact of our current climate crisis and the state of our planet and society.

The three top winners will receive cash prizes of $5,000, $2,000 and $1,000, respectively.

The prize created and sponsored by ASUs Julie Ann Wrigley Global Futures Laboratory, the Center for the Study of Religion and Conflict, and the Narrative Storytelling Initiativeoriginated as part of a project to rethink how climate change stories are told and explore their potential to drive social and cultural change. The project drew on the expertise of journalists, climate scientists and scholars of the humanities to better conceptualize and communicate through story the world-shattering stakes of inaction on climate change.

The winning narratives were chosen from nominations submitted by such renowned writers, thinkers and activists as Bill McKibben, Katharine Hayhoe, Wendell Berry, Vann R. Newkirk II, Frank Sesno, Kyle P. Whyte and Lacy M. Johnson.

The nominations were then reviewed and voted on by graduate students in a multidisciplinary course at ASU called Climate Narratives, Apocalypse and Social Change, developed with the support of a Luce Foundation/ACLS-funded grant and taught by ASU professors Steven Beschloss and Sarah Viren.

Weve launched this Climate Narratives Prize to shine a light on climate-related writing that can have an impact on the publics thinking and choices, said Beschloss, who is also the founding director of ASUs Narrative Storytelling Initiative and narratives lead for the Julie Ann Wrigley Global Futures Laboratory. It is clear it will take creative thinking and multiple modes of storytelling to expand the publics awareness and commitment to change.

To prepare for selecting honorees, we read widely and thought deeply about what it means to write toward social change, and students used that knowledge to evaluate each nomination, added Viren, an assistant professor of creative nonfiction. This process taught all of us to think more creatively about what it means to influence the way people think about an issue.

The public announcement and celebration of the winners will take place April 22 from 11:45 a.m.1:15 p.m. Arizona time in ASUs newest research building, ISTB7, dedicated to planetary and societal health.

Featured speakers include all three winners and several nominators in a conversation moderated by Beschloss and Viren. The event will include reflections on the issues surrounding climate change, the kinds of narratives that can drive impact, and the spectrum of storytelling from alarm and despair to optimism and hope.

Learn more about the Climate Narratives Prize and the project.

See original here:
Why some people become addicted and others don't - ASU News Now

Everyone considers sperm to be made exclusively by males. But did you know that females also make sperm? Well, it turns out that females also contribute to what makes a sperm a sperm. Nearly 20 percent of couples in the United States fail to conceive naturally after one year of trying, according to theCenters for Disease Control and Prevention. In species with internal fertilization, such as humans, the ability for a female to become pregnant and carry a pregnancy to term is dependent upon effective interactions between sperm and the female reproductive tract (FRT). When those interactions are defective, the result can be a failed pregnancy. Therefore, understanding the factors that contribute to sperm viability between copulation and fertilization is crucial.

Pictured are spermatozoa of Drosophila melanogaster within a females specialized sperm-storage organ, where they await the opportunity to fertilize ova. (Image courtesy: Scott Pitnick)

A research team from the College of Arts and SciencesDepartment of Biologyand Cornell University, led by Steve Dorus, associate professor of biology at Syracuse University, have been studying the life history of fruit fly (Drosophila melanogaster) sperm to better understand molecular continuity between male and female reproductive tracts. In other words, how the male and female reproductive tracts provide support to keep the sperm viable before fertilization. Their results, recently published in the journalProceedings of the National Academy of Sciences USA(PNAS), shed light on important events that may play a role in infertility that up until now have been poorly understood.

The team, which includes members from the Universitys Center for Reproductive Evolution, explored the compositional changes in fruit fly sperm, beginning shortly after they leave the testis, following insemination and finally after protracted storage within the FRT. Fruit flies are powerful model organisms for investigations such as this one because they are easy to culture in the laboratory, have a short generation time and their genetics are richly understood. In their study, the group uncovered that the proteome, or protein makeup, of the sperm undergoes substantial changes after being transferred to the FRT.

For species with internal fertilization, a sperms developmental journeyon the way to its final destination of fertilizing an egg and beginning a new lifetranscends both male and female reproductive tracts. After leaving the testis, sperm travel through the males seminal vesicles and descend through the ejaculatory duct, where they mix with seminal fluid proteins. The team found that many of these seminal proteins are progressively lost after sperm migrate beyond the site of insemination within the FRT. Conversely, female-derived proteins that may help the sperm with functions such as energy metabolism, begin to associate with the sperm immediately after mating, signifying a changing of the guard of proteins. After several days of storage within the FRT, the research team was surprised to discover that nearly 20 percent the sperms proteins had been replaced by female-derived proteins. The female contributions support sperm viability during the prolonged period between copulation and fertilization. This hand-off in the maintenance of sperm viability from males to females means that sperm are materially the product of both sexes, and this may be a crucial aspect of reproduction in all internally-fertilizing species, including humans.

By studying the intimate ways in which sperm interact with the FRT during the final stages of functional maturation, the teams research advances understanding of animal fertility and the contributions of each sex to reproductive success.

Their research, which appears in the March 15 issue of PNAS, was chosen as that editions cover art, signifying the high impact of their work. The photo was captured by co-author and biology Professor Scott Pitnick, and provides a close-up view of sperm within an organ specialized for sperm storage in a female reproductive tract of Drosophila melanogaster.

In addition to Dorus and Pitnick, other co-authors from Syracuse University included former postdoctoral researcher Erin McCullough and doctoral graduate Emma Whittington. Co-authors from Cornell University were Professor Mariana Wolfner and postdoctoral researcher Akanksha Singh. The teams research was funded by the National Science Foundation, the National Institutes of Health and a gift from Mike and Jane Weeden to Syracuse University.

Read the teams full paper, The life history of Drosophila sperm involves molecular continuity between male and female reproductive tracts.>PNAS is the official journal of theNational Academy of Sciences(NAS), and is an authoritative source of high-impact, original research that broadly spans the biological, physical and social sciences.

Link:
A&S Biologists Observe Molecular 'Hand-off' That Plays Key Role in Reproduction - Syracuse University News